<SEC-DOCUMENT>0001087294-13-000013.txt : 20131031
<SEC-HEADER>0001087294-13-000013.hdr.sgml : 20131031
<ACCEPTANCE-DATETIME>20131030184517
ACCESSION NUMBER:		0001087294-13-000013
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20131030
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20131031
DATE AS OF CHANGE:		20131030

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		131180406

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a8kpernixtherapeutics10242.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using WebFilings 1 -->
		<!-- Copyright 2008-2013 WebFilings LLC. All Rights Reserved -->
		<title>8k Pernix Therapeutics 10242013</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="se57746b43e3c41b78f4ba5c1c0972113"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;">FORM 8-K</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">CURRENT REPORT</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="51%"></td><td width="5%"></td><td width="44%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (Date of Earliest Event Reported):</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 30, 2013 (October 24, 2013)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;">Cumberland Pharmaceuticals Inc.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________________________________________</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td width="0%"></td><td width="33%"></td><td width="18%"></td><td width="5%"></td><td width="11%"></td><td width="33%"></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tennessee</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">001-33637</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">62-1765329</font></div></td></tr><tr><td><font>&#160;</font></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction of incorporation)</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(I.R.S. Employer Identification No.)</font></div></td></tr><tr><td><font>&#160;</font></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2525 West End Avenue, Suite 950, Nashville, Tennessee</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37203</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant's telephone number, including area code:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(615) 255-0068</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">____________________________________________</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Former name or former address, if changed since last report</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="se57746b43e3c41b78f4ba5c1c0972113"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01 Other Events.</font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 24, 2013 Cumberland Pharmaceuticals Inc. ("the Company") entered into an agreement with Pernix Therapeutics, LLC (&#8220;Pernix&#8221;) for the promotion and distribution of Omeclamox-Pak</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;covering the United States. Omeclamox-Pak is a branded prescription product that combines omeprazole, amoxicillin and clarithromycin for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease. It is the first FDA approved triple combination medication to contain omeprazole as the proton pump inhibitor and is prescribed over a shortened treatment period of ten days. </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With an effective date of October 1, 2013, the terms of the agreement provide for the Company to promote the product to gastroenterologists across the United States through its field sales force which also promotes its Kristalose</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;brand. Pernix will promote the product through its specialty sales force focusing on select primary care physicians. The companies will cooperate in the marketing and other activities needed to support the commercialization of the brand.  The Company acquired these product promotion rights for a combination of an upfront payment and future contingent consideration based on achieving revenue thresholds.  Additionally, the Company will also pay royalties on future sales. The Company and Pernix had no other agreements before this agreement was entered into. The Company announced the agreement on October 28, 2013 via a press release. A copy of the press release is attached as Exhibit 99.1.</font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="se57746b43e3c41b78f4ba5c1c0972113"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="68%"></td><td width="32%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumberland Pharmaceuticals Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">October 30, 2013</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">By: Rick S. Greene</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Name: Rick S. Greene</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Title: Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:15px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:384px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:384px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:384px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><hr></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit&#160;Index </font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.5625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="20%"></td><td width="13%"></td><td width="67%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release dated October 28, 2013</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pernixpressrelease-01.htm
<DESCRIPTION>PRESS RELEASE DATED OCTOBER 28, 2013
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using WebFilings 1 -->
		<!-- Copyright 2008-2013 WebFilings LLC. All Rights Reserved -->
		<title>Pernix press release - 01</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s8f3f5b62c8f641459697756e021b4272"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;"><img src="cumberlandpicture.jpg" style="height:155px;width:682px;"></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;font-weight:bold;">Cumberland Pharmaceuticals and Pernix Therapeutics&#160;Enter Into </font></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;font-weight:bold;">Exclusive Agreement to&#160;promote Omeclamox-Pak</font><font style="font-family:inherit;font-size:13pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:inherit;font-size:9pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;">&#160;</font><font style="font-family:inherit;font-size:9pt;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">- New triple therapy product&#160; for H. pylori</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">- Cumberland responsible for gastroenterologist promotion</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">- Pernix responsible for primary care promotion</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font><font style="font-family:inherit;font-size:9pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">&#160;</font><font style="font-family:inherit;font-size:9pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Nashville, Tennessee, and THE WOODLANDS, Texas (Monday, October 28, 2013)</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">-</font><font style="font-family:inherit;font-size:9pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Cumberland Pharmaceuticals Inc.</font><font style="font-family:inherit;font-size:12pt;">&#32;(NASDAQ:CPIX) and </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pernix Therapeutics, LLC</font><font style="font-family:inherit;font-size:12pt;">&#32;(NYSE: PTX) today announced an agreement for the promotion of Omeclamox-Pak covering the United States. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font><font style="font-family:inherit;font-size:9pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Omeclamox-Pak</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;is a branded prescription product that combines omeprazole, amoxicillin and clarithromycin for the treatment of </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Helicobacter pylori (H. pylori)</font><font style="font-family:inherit;font-size:12pt;">&#32;infection and duodenal ulcer disease. It is the first FDA approved triple combination medication to contain omeprazole as the proton pump inhibitor and is prescribed over a shortened treatment period of ten days. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font><font style="font-family:inherit;font-size:9pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Under the terms of the agreement, Cumberland will promote the product to gastroenterologists across the United States through its field sales force which also promotes its Kristalose brand. Pernix will promote the product through its specialty sales force focusing on select primary care physicians. The companies will cooperate in the marketing and other activities needed to support the commercialization of the brand. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font><font style="font-family:inherit;font-size:9pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;We have been searching for an FDA approved gastroenterology product that can be featured by our field sales force,&#8221; said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. &#8220;We have been very selective in the brands that we bring into our portfolio, and believe that Omeclamox-PAK is an excellent fit for our field sales organization. We look forward to featuring this important product to caregivers and their patients suffering from ulcers caused by </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">h. pylori</font><font style="font-family:inherit;font-size:12pt;">&#32;infections.&#8221;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font><font style="font-family:inherit;font-size:9pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dr. Brian Fennerty, M.D. Professor of Medicine, Division of Gastroenterology at Oregon Health &amp; Science University said, &#8220;Published studies show that a single ten-day regimen of twice-daily therapy with omeprazole, amoxicillin and clarithromycin eradicates 80 to 90 percent of </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">H. pylori</font><font style="font-family:inherit;font-size:12pt;">&#32;infections.&#8221;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font><font style="font-family:inherit;font-size:9pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Gastroenterologists are the leading prescribers of </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">h. pylori</font><font style="font-family:inherit;font-size:12pt;">&#32;treatments and we are excited to partner with Cumberland to reach that key audience for the Omeclamox-pak brand,&#8221; said Cooper Collins, Chief Strategic Officer of Pernix Therapeutics. &#8220;We believe that together we should be able to build a great brand from the strong existing foundation that has been created by the Pernix sales team.&#8221;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font><font style="font-family:inherit;font-size:9pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">VelocityHealth Securities acted as a financial advisor to Pernix Therapeutics for this transaction.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cumberlandpicture.jpg
<TEXT>
begin 644 cumberlandpicture.jpg
M_]C_X``02D9)1@`!`0$`W`#<``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`#3`Z`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]]****`"B
MBB@`HHHH`****`"BBB@`HHI&<*"3VH`6BOG'Q#^TP-7_`."GGAOX5:=J4_E:
M5X#O_$&KVL4Q$9DFO+6&W\Q0<%E6.8C/($G'WN?HZM:M%TU'FZJY$*D9WY>@
M4445D6%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44$X'-->3:A
M.1P,B@!U%>5?$#]LOX?_``WN9[6[\06VHZA;$K)8Z3$^H7,9]&2$,4_X%C\*
M\*^*7_!6^/PY%(OA[P#J%XPR%FU:_CLD^NR/S6_`[3770P->LTH1_3\R934=
M6?8[7"+U8#!QR:\`_;M_X*)_#[]A3X>7FH^)-5@NM=>%CIN@VLJM?7\FT[1L
MY*1YZR,`H]SQ7YZ_M'_\%:?C1XVM+BUT[5M*\'6DFY=NB6>+@J>S33-(V?=`
MAK\ZOC=K-[XGU6]U'4[V\U+4+QB\]U=S-//,WJSL2S'ZFOH\MX4E4FI8F5H]
MEU/.QF.]G%N!]M_\$'?V@_$'[5?_``6&^(_CWQ3.)M7\1>&+R>15SY5NGVFT
M5(4'9$0*H]A[U^XU?@#_`,&PXQ_P47\2_P#8G77_`*56M?O]7/Q;3C#'\D59
M*,4C#(9.6&O+75_F%%%%?,GM!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!110
M3@?2@`J#4M1BTJS>XGDCBAB!9WD<*J*!DDD\``5Y]^T3^TSX7_9S\)+J>OW3
M_:)RR6&GV^'N]1E`SLB3(SC/+$A5!R2!7QEXX^./B7]IS5A)XG>.VT$2;K;P
M];RL]FG(PT[$#[2_?Y@$4]%R-Q[,+@IUES[1[_Y$2J):'T_XH_;+A\52R6'P
M]TQ/$;ABC:O<RFWTJ(@\E&`+W&/2,;#T\Q:Y?Q-X%U'QMI#7'B_Q%J/B$R#<
MUC'_`*%I:^PMT.7'M,\E<]\.3^[C`X```'85Z3K/_(`_X#_2JJ)4Y)4_^#_7
MH"5]6?/OQ!TFUT&Q%I96\%I:PC;'%"@1$`[`#@"OFGXJ]9/K7T_\5_O2?C7S
M!\5>LGUKZ/+=;7,*VB/FOXH?ZQZ^>/BE_JY?Q_E7T/\`%#_6/7SQ\4O]7+^/
M\J^SP?0\3&_`SZK_`.#8C_E(OXD_[$ZZ_P#2JUK]_J_`'_@V(_Y2+^)/^Q.N
MO_2JUK]_J^$XQ_Y&+_PHZ>'_`/=?F_S"BBBOECW`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@!&8(N2<`5X_\`MC_M?:#^R1\-FU?4"+[5[_=;Z1I2/MEU&<#.
M,_PQJ,%W/"CU)4'T#XJ_$K1OA#\.M:\3:_>Q6&D:%:O>7<SG[J*,X`ZECP`H
MY)(`Y-?B#\=_VG-9_:X^-]_XPUAI(893]GTNP+Y33+-6^2(=MQ^\[?Q,3V"@
M>SE&5O%3<Y?!'?S\CFKUN33J>C:E\4=?^-_Q"NO%/BB_.HZS??)N"E(;6($E
M8(4R=D8].K')8DG->M_#O[D7U%>"_#P;O+QSTKVSP1XFL=/O(;1YUEOGP4LX
M$:>ZE_W(8P9&_!37TN,IQ@DDK6_`RIZ[GT;\.?N1_05Z3K/_`"`/^`_TKS/X
M:^'/&NJ0(^F^`O$3Q\8FU+RM,B/_``&9A,/^_1KTE?A!\2O$EH(KBY\'>'HN
M,JL5SJLF/KFW4'\Z^1KI<]^9?>=46TCP?XL.`S\^M?,/Q6X,F?7-?H)=?L%C
MQ#('UGQSXGG9N7CL;.SMH3]`\,CC_OL_6GP?\$P?A1<X.IV7B+5Y!U:XURYB
M#_5871?TKT\+F5"C;F;?HO\`.QG*$IZ(_&7XH#]Y)[5\[_%-L)+P>_:OZ,+7
M_@F'\"+:0,WP[TN[8=[NYN;K_P!&2-5I?^":?P"`.[X1^!9<]?-TJ*3_`-"!
MKV*7%F&I[0;^XX:^7SG&US\</^#8MQ'_`,%%_$N3C_BCKKCO_P`?5K7[_;AC
M-?GI_P`%)_V:?`'[,.@^$M3^'7A#0/`^HZA<W,%S<Z)9I8S3QB-#L9XP"5S@
MX)QQ7RA%\:/&.BR!K3Q9XEMBG(\O5)UQ^35\WG>9QQV)]O"-E9+7R-LMP<L-
M1]G+75_B?MV2!U-&><5^,FC?MT?%WP<X-CX^U\XYVW,JW2_B)0V?QKT;P)_P
M66^*GA"2--8M?#GB6$<.9K4VTS#V:(A1^*'Z5Y!Z!^JM%?$_PI_X+<^`_$K1
M6_BS1-8\+SM@//$/MMLOOE0'Q_P`U]4_"?X]>#?CCI1O/"?B71]>B49=;6X5
MI8O]^/[Z'V8"@#KZ*`<T4`%%%%`!1110`444-P#GI0`45\T?\%#/^"J/PM_X
M)O>'=/G\;:C=7FM:PK/IVAZ9&L]]=JIP9""RJD8/&]V`)!`R0<?"-W_P=U^$
M([IQ!\&?$LL&?D:37((W(]P(F`_,UZF$R3'8FG[6C3;7?1?F>?7S3"T)>SJU
M$GV/V%HK\=Q_P=W^%/\`HBOB#_PH(?\`XS1_Q%W^%/\`HBGB#_PH(?\`XS77
M_JOFG_/I_>O\SG_M[`?\_5^/^1^Q%&>:_'?_`(B[O"G_`$13Q#_X4$/_`,9K
ML/@S_P`'7GPE\;^*;:P\7>!_%G@JTN)%0WZRQ:E!!DXW.$VN`/55:HGPUF<8
M\SI/[T_U*AGF!DTO:K\3]6**R?!'C;2?B-X3TW7=#U"TU72-8M8[RRO+6420
MW4,BADD1AP5((((]:UJ\-IIM,]5.ZT#/-&:^9/\`@J-_P4@L?^"9?P6TGQIJ
M/A>]\66VJZNFE"UMKM;9D+122;]S*PQ^[QC'>OGS_@GK_P`'#&A_\%!/VI=%
M^&.G?#35_#5SJ]M=7"WUQJT=RD8@A:4@H(E)R%(Z\5Z%+*L54P[Q4(>XMWIT
MW..IF&'IUE0E/WGT]=C]'J***\\[0HSBBN(_:-^,2?L^_`WQCXXELI=2@\(:
M)=ZS):QN$>X6")Y"@8@@$[<9(-.,7)J,5JQ-V5V=OFBOQYM?^#N3PMJ%[#`G
MP7\0)YKA,G7X3C)`_P">-?L)$Q:-21@D#(]*[,;EN*P=OK,>6^QR87'T,3?V
M$KVW'445\O?\%3?^"EUC_P`$Q/A)H/B[4?"EYXLM];U8:6+>VO%M6B8Q22;B
MS*P(^3&,=ZPP^'J5ZBI4E=O9&]:K"E!U*CLD?4-%?GE_P3J_X.%O`G[?GQW_
M`.%?S>%K[P#K%[;--I+7VHQW,>J2*<O`K!%VN$^8`YW8('(P?T,5PW0@_C6F
M,P=;"U/98B/*R,+BJ6(A[2E*Z%HHHKE.@***\C_;<_;$\+_L-?LZZ[\1?%$P
M:QT>,+!:1N!-J-RW$5O'G^)C^0!/05=.G*I-4X*[>Q,YQA%SD[)'KF:*_(7P
MC_P=D^%_%WBS2M(C^#6OV\FIWD-H)3KT3",R.$W$>3R!G.,U^N]N[20J6&&(
MYKKQN6XK!M+$PY;['+@\=0Q,7*C+FL/HS01D5\I?\%5?^"H>G_\`!+KX>^%O
M$.H^$KWQ=%XHU&33DAM[U;4P,D1DW%F1L@@8Q7/A\/4KU%2I*\GL;UZT*,'4
MJ.R6Y]6T5^.X_P"#NWPJ3C_A2GB'_P`*"'_XS1_Q%W^%/^B*>(/_``H(?_C-
M>S_JQFG_`#Z?WK_,\S^WL!_S]7X_Y'[$45^._P#Q%W^%/^B*>(/_``H(?_C-
M'_$7?X4'_-%/$'_A00__`!FC_5C,_P#GT_O7^8?V[@?^?J_'_(_8BC/.*_'_
M`$G_`(.Z/!-QJ4*7WP<\46MH6Q)+!K,$[H/4*8U!^FX5^B7[#7[??P[_`."@
M?PN/BKX?ZL;N&V<0ZA87,?DWNES$9$<T>3C(SA@2K8.":XL9DV-PL?:8BFU'
MONOO1TX7,\+B)<E*HF^Q[=10#D9'(--E)6)B.H'%>:M3O'9HK\DOBA_P=:>&
M/A?\2_$?AJ?X/:[>R^'M4N=,>=-=B03&&5HRP7R3C.W.,]ZQ!_P=W>%#_P`T
M4\0?^%!#_P#&:]V/#.9R2E&E=/S7^9Y#SW`IM.HE;O<_8BBOQW_XB[_"@./^
M%*>(/_"@A_\`C-'_`!%W^%/^B*>(/_"@A_\`C-5_JQFG_/I_>O\`,7]O8#_G
MZOQ_R/V(HK\=S_P=W^%!_P`T4\0?^%!#_P#&:[K]F+_@YZ\._M.?M$^"OA[9
M_";6](N/&6KV^DQWDNM13);-,X0.4$0)`STS45.&\RA%SE2LEYK_`#*AG>"E
M)1C55WZGZG4$X%(IR!GK7'?M%?%N/X`_`#QOX[ELI-1A\%Z#>Z[):(X1KE;6
M!YC&&((4L$(R0<9KQ8Q<FHQW9ZDI**;?0[*BOQT7_@[L\*+_`,T5\0?AX@A_
M^,T__B+N\*?]$4\0?^%!#_\`&:]S_5C-/^?7XK_,\IY[@/\`GZOQ/V(HK\=_
M^(N_PI_T13Q!_P"%!#_\9H_XB[_"F?\`DBGB#_PH(?\`XS3_`-6,T_Y]/[U_
MF+^WL#_S]7X_Y'[$9YHK\>K/_@[L\'2WT2W/P:\30VY8"1XM;@D=%[D`QJ&/
ML2/K7Z`_L#_\%*/AO_P48^'MWKG@#4+D7&DR)%JFE7\0AOM-=P2N]`Q!5L-M
M=25.UAG((KDQF2X["Q]I7IM1[[K\#IPV9X6O+DI339]"4=**CN79$&WJ3BO+
M.\DS17Y1_'[_`(.E?#?P'^-_C#P//\(M=U"Y\(ZS=Z/)=IKD4:W#03-$7"F(
MX!VYQDU]_?L'_M7V_P"W#^REX3^*5IHT_A^V\5I<21V$TXG>W$5S+;G+@*#D
MQ$\#O7?BLKQ>'I1KUX6C+;Y['%0S'#UJCHTY7DMSUZBBBN`[0HHHH`****`"
MBBH-1OH].L9;B61(H85WR.[`*BCJ23P`!WH`GSBBOR0^)7_!V1X%\&>/];TC
M2/A=K?B33M,O9K6UU2/68[=-01&*B54,1*JV,C)Z$5]V_P#!-_\`X*#^&?\`
M@HY^SQ%X[T&W;2)XKR6PU#29[A99].F0@@,0!D,A5U.!D-Z@UZ6+R?&X>FJU
M:FU%G!ALRPU>;ITYIM=#Z"HHHKS3O"@G%%)(2J$@$D#C%#V`6BOS6_;R_P"#
MB_0OV%/VIO$GPQU#X8:QXBN?#PMRU_!J\=NDPE@2480QL1C?CKVKZA_X)V?\
M%)/`/_!1OX0KXE\*7:V6J6F(]7T*YE4WFDR^C`?>0_PR`88>AR!Z%;*L72HK
M$U(6@]GZG#1S'#U:KH0G>2Z'T110"&&0<BBO/.X***\^_:K^/$?[,/[.OC'X
M@S:=)J\'A#2I]4DLXY1$]PL2[BH8@A2?4BJA"4Y*$5=O0F4E&+E+9'H.:*_*
M?]GC_@Z.\-_M!?'?P9X$MOA'KFFW/C#6K31H[N37(I$MVGF6(.5$0)`W9QGM
M7ZJP,7A4GKWKKQN7XC"24<1'E;U6WZ'-A,;1Q,7.A+F2'T$XHKF_B_X_'PK^
M&'B'Q*UNUW'X>TRYU-X%;:TRP1-(5![$A<9]ZXTFVDCJ;25V=)17XZI_P=V^
M%`@)^"GB#T/_`!4$/_QFG?\`$7=X4_Z(IX@_\*"'_P",U[O^K&:=:7XK_,\E
MY[@;_P`5?B?L117X[_\`$7?X4(_Y(KX@_P#"@A_^,T0_\'=GA)YP)/@QXD2/
MN5UZ!C^1A'\Z/]6,T_Y]/[U_F"SW`?\`/U?C_D?L117YG?"+_@Z:_9\\>ZA#
M;>(M,\;^"3*0IN+W3X[NWC/N;=W?'OL_"OO;X"_M*>!OVG?!4/B/P%XKT3Q7
MHLWRFYT^Y641/_<=?O1N.ZN`1Z5YV*RW%X7_`'BFXKO;3[]CMP^.P^(_@S3?
M:^IW=%(&##(((J&_U"'3K:26:6.&.)"[.[!54`9))/0<5Q'5>Q.3BC-?(6H?
M\%A/!GB/Q%?V/PW\$_%/XRVVE3-!>:IX,\-R7FEQ2*3E%NG9(Y&_ZYEL]LUZ
M/^RK_P`%#/AY^UCXBU+P]I-UJWA[QIH<?F:GX5\2:=)I.M6*\?.UO+@LG(^=
M"RC(R1FNJ>!Q$(>TG!I+?^NASQQ5*4N521[M12!@PR""#2URG0%%%0:E,MM:
M-([!$C&YF/\`"!UI!?N?F+_P7X_:KD_MOP_\']+NML3(FN:\%;&X9(M86_X$
MK2D>T9KY1_91_9L\<?M):X;+P=H,^J);/LN;V1O)L;,]<2S$8#8.=B[GQ_#7
MLO[+O[&>I?\`!5?]L7X@?%GQ1->6'PXDU^9(9D)6;65A8116\3?P(D,<8=QR
M#E1\V67];?AM\.-%^$O@VS\/^'=+L=&T?3D\NVM+2(1Q1+]!W)Y)/))YS7VE
M;,J>78>.$H*\UK+U>_J>;2I2K3=66W0^3OV>O^"1&A^&;..Z\>^(+_Q%>@#=
M8:<[6-@GLS*?.D^N]%(_@KZF^'OP7\+_``GTT6?AK0M)T.WP`5L[5(B^.[$#
M+'W))KJ**^5KXRM6=ZDKG?&G%;"*-J@>E+117,6%%%%`!1110!\5_P#!9S_D
M1?`W_7_=?^BDK\\[_J:_0S_@LY_R(O@;_K_NO_125^>=_P!30!E7G4_2LFZ^
M^?K6M>=3]*R;K[Y^M`&5=_Q?Y[5!HOBO4_!>M1:CH^H7NEW]NVZ.XM9FBD0^
MS*014UW_`!?Y[5DWGWC0!]S?LG?\%B_&W@HV^G^.[=?&&E*`INU`BU&(=,[A
M\LGT8`G^]7Z+?`O]I#PC^T5X?%_X6U6&\"*#/;-^[N;0G^&2,\K]>A[$U^$?
M@SJGUKVGX0^+=4\">(+75=&O[K3-1M3F*XMW*.N>H]U/=3D'N*`/VNHKYL_9
M*_;JM_BFUKH/BT0:;XB<".WNDPEKJ1]!_P`\Y#_=)(/\)_A'TDC;U!Z4`+11
M10`4V;F%^<<'FG4C_</TII`?S!_\'"?Q*O/B)_P56^(<%S</-;^&%LM'LUW9
M6&-+6.1E`[?/*Y/N37J/_!,[_@WS3_@H=^RMIOQ+;XIMX4.H7MU9_8!X?^V!
M/)D*9\SSTSG&?NUX%_P6]_Y2L?&G_L-K_P"D\-?M3_P;._\`**GPU_V&]4_]
M*&K]4S+&UL#DU&>%ERMJ/1/=7Z^A^?9?AJ>*S6M#$+F2YG^-CY5_XA#8C_S7
MEO\`PD?_`+KH_P"(0V'_`*+RW_A)?_==?M517Q:XJS3_`)^_A'_(^G_U>R__
M`)]K\?\`,_%4_P#!H="!C_A?+G_N4O\`[KK\Q/\`@HA^QX/V#OVL?$7PQ&OG
MQ-_8,=N_]H&T^R^=YL"2X\O>^,;\?>/2OZY3R#7YK_M^_P#!NAHW[>7[4OB#
MXG7OQ3U3PW<:\ENC6$.BQW*0^5"D7#F52<[,].]>SD?%M95W_:%3W+=EOTV5
MSR\UX<I.BOJ<$I7[O;YLW/\`@V4^)U[\0?\`@F7IUA?3O._A37+[28"Y)*P9
MCG1?HIG8>P`%?H97S9_P2_\`^"=EG_P31^`M]X$L?%%UXLAO=6EU7[9/9K:L
MIDCB39L#-P/+ZY[U])U\GF=:E6Q=2K1^%MM'T>7TZD,/"%7XDE<_+C_@Z_\`
M^3#O"'_8Y0?^DMQ7YR?\&V'_`"EE\%?]@O5O_2&:OT;_`.#K_P#Y,.\(?]CE
M!_Z2W%?G)_P;8?\`*67P5_V"]6_](9J^^RG_`))VKZ3/C\T_Y'-'_MW\S^F*
MBBBOS,^["O$O^"DG_)@'QN_[$76/_2*:O;:\2_X*2?\`)@'QN_[$76/_`$BF
MKHPG\>'JOS,J_P##EZ'\D>@?\ARS_P"N\?\`Z$*_M(3[@^E?Q;Z!_P`ARS_Z
M[Q_^A"O[2$^X/I7W7'OQ4?\`M[_VT^-X.^"I_P!N_J+7Y4_\'9G/[%O@#_L<
M5_\`2.XK]5J_*G_@[,X_8M\`?]CBO_I'<5\QPY_R,Z/^+]&?19W_`+C4]&?@
MSX+\3:Q\/?$>F^(]%N;O3=1T>\2XL[Z`E&MKA"&1E;^\,9_"OZC_`/@D+_P4
M6TW_`(*-_LO6?B)WMK?QEH833_$UA&<>1=!<B55[12@%E]#N7JIK\1_^"57[
M!,W_``4%_8R_:4\-Z6J-XN\,S>'=<\.[B%$ERJ:JKP$]A+'\OIN"'M7DW_!-
M3]N;Q)_P3)_:ZM/$;P7JZ7YQT?Q5HT@*//;;\2*5.`)HF&Y2<$%2O`8U^@9[
M@J69PJ4J=O:TMN[32=O1_F?&Y/BI8%TZD[NG4_!IVO\`UT/ZOJ*YWX4_$_1/
MC)\/=%\3^'+Z'4]"UVSCO;&[A8%)XG4,K#\#R.QR#R*Z"1Q$A8]!7Y+*,HOE
MDM3]&335T$F`IST(YK^;?_@X'_X*5/\`MK?M+KX&\*WSW/P^^'EP]I;-`VZ/
M5[_[DUQQ]Y5(\N,^@8C[]?IC_P`'"W_!3$?L=_LWCP/X7O3!\1/B/;2VL31O
M^\TJP^Y-<\<JS9,<9]=Y_@K\CO\`@D/^P/J7[4_C;Q?X\O;5QX)^%6B7FKW5
MPZ?)=WR6LCVMNN>I#J)&]%3G[PK[GA?`TZ%.69XG1+2/KM=>?1'RF?8N=:K'
M`4-WK+T_K<^7/@H#_P`+B\)GG_D,V?\`Z/2O[*XO]4OTK^-7X*C'QC\)^G]L
MV?\`Z/2O[*HO]4OTK;CQ>_1])?H8\(_PZO\`B7Y#J_(__@[C_P"3:?A+_P!C
M1<?^DC5^N%?D?_P=Q_\`)M'PE_[&BX_])&KYSAG_`)&='U?Y,]O/O]PJ>GZH
M_*;_`()=_L*0?\%%/VI[?X;S^))O"T<VEW6H_;H[,73#R0OR["Z]=W7/:OTH
M'_!HIIA_YKA?#V/AI/\`Y)KY7_X-C6V?\%1K`XS_`,4SJ7\HJ_I#2Y`0#*\#
MU/\`A7T_%>=XW"8WV6'G9<J>R>_J>!D&5X3$83VE>%W=_AZ'XR?\0B>F?]%Q
MO?\`PFD_^2:7_B$5TQ>OQOOC_P!RTG_R37[-_:AZK^9_PI#=J.Z_G7S/^M>:
M=:OX1_R/:_U?R[_GW^+_`,S^8'_@K1_P1SUS_@EV_A;4'\5VOC+PWXK>:W@N
MUL393VT\2JQC>/>X(96RK!OX6!`XS[;_`,&J7Q"U'0/V]O$_A^&:3^S-?\(W
M$MS"3\AEAN+=HY,>JAY!]'-?27_!W%XGL7^#/P>TK[3$-1?6[ZZ6WW?O#$L"
M*7QZ!F4?4U\J_P#!K5IMQ=?\%(=3GBAD>&S\&WSS.!Q&#/:J,_4L!^-?;+&5
M<7P_.KBM96>O?6R/FUAJ>'SJ%.AI&ZT^1_1;&,(.U*_W#]*2'F/\3_.E?[A^
ME?E4%;0^_9_'9^UG_P`G4_$S_L:]4_\`2R6OT?\`V//^#96/]J_]F+P1\1C\
M8VT(>,=)AU,6'_"-BX^S;QG9O^TKNQZX%?G!^UG_`,G4_$S_`+&O5/\`TLEK
M^GG_`(([2"+_`()A_!#//_%)VG3Z&OUCB/,L3@\%1GAI6;LMD^E^I^=Y!@:&
M)Q52->/,EK^)^>'_`!"'1$_\EY;G_J4O_NNC_B$-A_Z+RW_A)?\`W77[2BZ7
M%#7:J,X-?%/BG-5_R]_"/^1]7_J[E_\`S[7X_P"9^+1_X-#8?^B\M_X27_W7
M7??LK?\`!L,G[+O[2W@7XAI\9#K9\&:S;:O]A/AK[.+KR9`_E^9]I;;G&,X-
M?K6C[UR.E+6=3B;,JD'"=31Z/1?Y%0R'`0DI1IJZ]?\`,1>G?I7C/_!1[_E'
MG\=_^R>Z_P#^FZXKV>O&/^"CW_*//X[_`/9/=?\`_3=<5X^#5JT%YK\STL3_
M``9^C_(_D8TRT^WZA;P;MGGR+'NQG;EL9K]JK;_@T=TRZMTD'QNOUWJ&P?#2
M<9'_`%\5^+7A_P#Y#MC_`-?"?^ABO[/]'_X\(_\`<7_T$5^G<79IBL&J7U:7
M+>]]$]FNZ/@N&<NP^*C4]O&]K6WZGXT_\0B>F_\`1<+[_P`)I/\`Y)I/^(13
M3`1GXWW_`"?^A:3_`.2*_:&BOB_]:<T_Y^_A'_(^I7#V7_\`/M?C_F?S!_\`
M!6?_`((Q:[_P2^L_#FM#Q9;>-/"OB2Y>RCO%L393V=PJ;Q')'O<$,H8A@W\#
M9`XSZ/\`\&NGC?4/#W_!2:?2+>9EL/$'A>]CNXLG:_E-%+&V/4%2![.:^X?^
M#LCG]B;P+T./&4?_`*1W%?!'_!LC_P`I2M'_`.Q=U/\`]%K7VE'&5<;D%6KB
M7=VDNVQ\S/"4\+G5.G0T3:_$_I*!YQ22]%_WA3J;+T7_`'A7Y5>ZN??/8_D3
M_P""BW_)_OQJ_P"QXUC_`-+9:_HH_P""`'_*(?X.?]>NH_\`ITO*_G7_`."B
MW_)_OQJ_['C6/_2V6OZ*/^"`'_*(?X.?]>NH_P#ITO*_2^+?^170]8_^DGP_
M#W_(QK?]O?\`I2/L:BBBOS4^Z"BBB@`HHHH`*_.W_@XP_;_/[*/['5SX+T2\
M^S^,?BBLFE6QC?$EK8``7<WJ-RMY0/K(2/NU^@GB36;7P[HMSJ%]/%:V=E&T
M\\TK;4AC12S,Q[``$GV%?RI?\%3/VS]0_P""B/[<FO\`BBQ6YN-'-RNB^&;-
M,L5M(VV1%5_O2N6D(QG=+CM7TW"V5_6\7[2:]V&K_0\+B#'?5\,XP?OST7ZG
M'?LY_L+>.?VG/@C\4?'OANS,NB_"K3H]1U'*$M=;GRT<78LD*R2L.<*@_O"O
MH_\`X-\?V^Q^QS^V5;>'=;O?L_@?XF-#I.H>8_[JSNPQ%K<Y/``9F1C_`'9,
MG[HK]M?^"4O[!EC^Q!^PAX?\#WUG;3ZWJMN^I>)@R!A=7EP@\V-N/F5$"1#U
M$>>]?SS_`/!5[]B:Y_8&_;7\3^#X(I4\.W4O]K>'9N</8S,6C4'UC8-&?=,]
MZ^OPN;4LVG7P-3X6O=[Z:7^_4^:K9?4RZ-+&0UE]KY_\#0_K`HKXL_X(7?M\
MI^W1^Q7I4^JWJW'CCP6L>A^(`S9EN'C3$-T<\GS8QN)_OA_2OM.OS+%8:>'K
M2HU%JG8^\H5X5J<:D'=-7"BBBN<U9_,%_P`'#!/_``]E^)8[%-._](8*^>?V
M3?VKO'7[$/QNTKQSX(U";3-6LB/,@DW&VU"W;!:&9.-\;K^7!!!`(^AO^#A?
M_E+-\2\]/+T[_P!(8*]_\'_\$AY_V^?^"+_PJ^)?@*UB'Q4\+VVIV;VO`_X2
M.SAU.[58<D@"9`#L)X(^4]B/V.GC,/1RW#QQ2O":C'RU74_,ZF'JU<?6=!VE
M%MJW6S/UI_X)G_\`!2OP9_P4@^"=OK_AZ6.P\0:>JQ:[H<DH-QIDV#SCJT3$
M$HX&",@X(('TK7\@?[,_[2WQ!_8`_:(MO%/A>>ZT+Q/X>N6M[^PNHV5;A5($
MMK<Q$@E3C#*>01D$$`U_3#_P3(_X*<>"/^"D?P936M`8:9XETW;%KF@S2AI]
M.E/1@?XX6YVN!S@@X((KX3B'AZ6"E[>CK2?X>OEV9]?DV<QQ4?9U-)K?S/IN
MOGC_`(*S_P#*-;XV_P#8H7__`**-?0]?/'_!6?\`Y1K?&W_L4+__`-%&O!P/
M^\T_\2_-'K8O^!/T/YGO^":__*0KX(?]CSH__I;%7]<MO_J5^E?R-?\`!-?_
M`)2%?!#_`+'G1_\`TMBK^N6W_P!2OTK[+CS_`'BC_A_4^7X._P!WGZ_H/KSC
M]K__`)-6^)?_`&*>J_\`I))7H]><?M?_`/)JWQ+_`.Q3U7_TDDKXG#_Q(^J/
MK:GPL_CWM(?M%S''NV^8P7.,XR?2OV9\/?\`!I+'X@T&ROF^.KPF]MXY_+_X
M1/=LW*&QG[6,XSUK\:--_P"/^#_?7^=?V:_#W_D0=$_Z\(/_`$6M?J'&&;8O
M!>S^K3Y;WOHO+NO,_/\`AK+</BO:.O'FM:V_F?C8?^#0Z%5)_P"%\MQ_U*7_
M`-UUE>(?^#1758[5GTGXY:?-+CY8[OPL\:D^[I=-_P"@FOW`HKXR/%F:)W]K
M^"_R/J'P[E__`#[_`!?^9_,I^US_`,&]?[0G[*V@7FNP:7IGQ`T"Q4O-<^'9
M7FN(4'5FMG59,`9)*!L`$G%?//[%7[</C[]@CXTV?C'P/J<UK+"ZKJ.F2NQL
M]6A!^:&=!U!&<-U4X(K^NZ>'SACCT/O7\^/_``<U_L":-^SG\?-!^*/A:PBT
MS1OB4\\6J6L"!88=2B"LTB@<#SD;<1CEE<]S7T^1<1O,)_4<?%/F32??RMW/
M`S7(U@H_7,&VN7=?Y'[:_L2_M?>&_P!M[]G/PY\0_"\G^@ZS#BXMF;,NGW*G
M;+!)_M*V?J"I'!%>%_\`!<GQ3JMA^REX>\*:;J-QI$'Q3\;:/X*U.]@;9);V
M-W)(9]K=MRQ[/HY'>OSY_P"#3K]I^YT+XP>/?A%>7#MINO6(\1Z;$S?+%<PE
M(9\#U>)HR?\`KB*_7/\`;K_9&TW]MO\`9PUWP'J-[)I4UZJ76FZE$I:72[Z%
MA)!<*,C.UP,C(R"1D9KY3&8..79I[*?PIIKT?^7Z'T>$Q4L9@/:0^*UOGU^_
M]3\[/VV$\`?LR_MRWGA;5]&^-2?"GP)\*["[M=,^&^H75K#HQ6[G1KJY$,\2
MA"@P9&SEL9SUK!\>>$_&OPG_`&#OA?\`M`>()=8MO'_@KXC6\_@Z^U6]2[UJ
MZ\*W]VL4-A?7"$^=O@ER>3@=,9(KV#P)XU\?_`;XZ:SXE^/'P.^*7C?Q??\`
MA*+P->:KX$T^#7?#OB&SCG>07'E%HY8)9-Y#(XV\G@`XJM^RI^PE\0OV@M5\
M#:!XGT+Q1\/_`-G+X6ZZ_B7P[X;\574-QX@UFX5V>TMYEB!$-G;LQ*QR,[D`
M`\8V^G[:%.$74DK1M=WOS:--15]W^*WL<;IN;ER==E;;5:OT]?O/TYM\F%#G
MC%24R!/*B5?[HQ3Z^,5NA]&%87Q,\.7OB_X>ZYI>G72V-_J-A/;6URREA;R/
M&RJY`Y(!(./:MVH[N[BL+62>>1(885+R2.P544#)))Z`"J3L[H35U8Y#]GSX
M):/^SK\%O#/@G0X$ATWPU81V41"@-*5'S2-ZN[%G8]V8FNSI(W61`RD,K#((
M.012T2DY-RENP225D%%%%(84444`%%%%`!1110!\<_\`!8'PQJ?B?P3X*33=
M.O\`47AOKDNMK;O,4!C4`D*#BOS^U3X<>(H"V_0-<3'7=82C'_CM?N,R!NHS
M044]AQ0!^#&K>'-1LE8S6%["!D'?`ZX_,5SU]$T3?,K+GU%?T"36,-RI$D4<
M@/4,H-9&K_#'PUX@0K?^'M#OE/47%C%+G_OI30!_/W><%JR+P<D^M?O%XI_8
M=^$'C!'%]\.?"99\DM!8);L?^!1[37DWCG_@C7\$O%^]K32M:\/R/_%8ZG*X
M!]=LQD`^E`'Y+>#.J?6O6/!G\-?6?BS_`((7_P!D%Y/"7CEI-IRD&K6>,^WF
M1G_V2O,O%/[`GQ2^#FZ6\\-2ZK8Q];K27%XG'4[%_>@>Y04`4?"<:R*`PROI
M7VU^R+^TY/K8M?"OB6Y:6^(":;?R'F\`'^JE/_/0`<-_&,]P=WQ-X3S%.\3@
MI+$=KHPPR'T(/(/UKU3PG`MU&HWNC+@I)&Y5XF&"&4CD,"`01R"!0!^B(8$D
M#M2UYY^SI\67^)/@YH=0=1KFDE8;U0-HFR"4G4=E<`G`Z,&':O0Z`"D?[A^E
M+2/]P_2FMQ,_E6_X+>_\I6/C3_V&U_\`2>&OVJ_X-G/^45/AK_L-ZI_Z4-7X
MJ_\`!;W_`)2L?&G_`+#:_P#I/#7[5?\`!LY_RBI\-?\`8;U3_P!*&K]*XB_Y
M$E#_`+=_])9\-D?_`"-ZWI+_`-*1^@%%%%?F:/N@HP,YQS2-G:<=>U?*_P"T
M-_P6;_9W_9/^+FI^!?B!\0'T+Q/I*Q/<V?\`8&I77E"1`Z_/!;NARK`\,>M;
M4:%2M+EI1<GOHK_D9U:\*4>:I*R\]#ZIQ17E/[)'[9?P^_;?^']QXL^&NOMX
MC\/VMY)I\ER;"XL]LZ!6*[)XT?A77G&#FO5JFI3G3DX5$TUT94)QFN:+NC\N
M/^#K_P#Y,.\(?]CE!_Z2W%?G)_P;8?\`*67P5_V"]6_](9J_1O\`X.O_`/DP
M[PA_V.4'_I+<5^<G_!MA_P`I9?!7_8+U;_TAFK])RG_DG:OI,^&S3_D<T?\`
MMW\S^F*BBBOS,^["O$O^"DG_`"8!\;O^Q%UC_P!(IJ]MKQ+_`(*2?\F`?&[_
M`+$76/\`TBFKHPG\>'JOS,J_\.7H?R1Z!_R'+/\`Z[Q_^A"O[2$^X/I7\6^@
M?\ARS_Z[Q_\`H0K^TA/N#Z5]UQ[\5'_M[_VT^-X.^"I_V[^HM?E3_P`'9O\`
MR99X`_['%?\`TCN*_5:ORI_X.S?^3+/`'_8XK_Z1W%?,<.?\C*CZ_HSZ+._]
MQJ>C/(_^#090]Q^T$"`0?^$<&#_W%:Q_^#E;_@E4_A+5I?VA?`^FJNG:E*L?
MC&TMX_\`43L<)?X'\+G"2?[11N=S$;/_``:"?\?/[0/U\.?^Y6OV6^(O@72_
MB9X,U+P_K=A;ZIH^LVTEG>VDZ;X[B)U*LK#T()KV,TS*I@<]G7AMI==URK0\
MO+,##%Y/"C/SL^SNS\/?^#:7_@J6/AIXTC^`/CG4MNA:],\OA.[GD^2QO&^9
M[/)Z),<E/23(_C%?M'^T1^T%X:_9G^"7B3QYXJO19:#X9LGO;F0\,^T96-`>
MKNV%4=V8"OYD?^"JO_!/S7_^"8W[6\^EV,E\OAC4)SJOA+5U+*YA#@B/>.DT
M+X4\YX5N`PKIO^"@?_!9OQU^WM^S)\._AUJZ26`\/P>9XFN4D`7Q%?(62&4@
M=%6,!R#QYCL?X5KU,PX>IYA7I8W"/]W/67E_P^WDSBP>=3P=&>&Q7QP^'S_K
M\CSGXL>//B-_P5\_;Z>YM;:2^\3^/]36QTJQWDPZ7:@XCCS_``Q11Y9FQV=N
MIK^B#X<_L7^'?V#/^":/B?X=^'8XY(],\):E)?7VP+)JEV]JYFN'[Y9N@/10
MHZ"OE?\`X-O?^"7S?L[?"$?&;QAI@B\9^.;<+H\,R8DTG3&Y#8ZB2?ACW"!!
MW85^A_[5W_)LGQ$_[%?4_P#TEDKR>(<UC4KPP6&TIP=O5K_+8]+)LME2IRQ5
M;6<_P1_(I\%?^2Q^$_\`L,V?_H]*_LJB_P!4OTK^-3X*?\EC\)?]ABS_`/1Z
M5_97%_JE^E>AQ]_%H^DOT.#A#^%5_P`2_4=7Y'_\'<?_`";1\)?^QHN/_21J
M_7"OR/\`^#N/_DVGX2_]C1<?^DC5\WPS_P`C.CZO\F>YGW^X5/3]4?AIX'\?
MZ]\-M=&I>&];U?P_J2QF,76FWDEK.%.,KOC(;!XR,]J[#_ALGXO*?^2J?$;C
M_J9+W_XY7UM_P;4>'M/\5?\`!3BQM=3L;/4;5O#6I,8;F%98R0(\':P(SS7]
M%D7P3\&F-2?"?ALD@?\`,-A_^)K[W/>(J6!Q7L945/1._KTV9\AE&2U<5AU5
MIU7%7>FO^:/Y'?\`ALKXO9_Y*I\1O_"DO/\`XY1_PV3\7F/'Q3^(WX>)+S_X
MY7]<G_"DO!O_`$*?AK_P60__`!-'_"DO!N,?\(GX:_\`!9#_`/$UXW^NM'_H
M&7WK_(]/_5C$?\_W^/\`F?Q[ZOXWU/XJ^,K2Z\:>*-<U#S'6.;4;V634;B&/
M/)`D?<V.N-PK^B#_`(-[_P!E#X'_``=_9^OO%_PN\8I\1-=\2A+?7-8EMOLL
M]DR886?V=LO"%)W?,3O.&R1C'SC_`,'4_P"R/X%\"_"#X??$?P]X9TG0M?GU
MQ]$O[C3[9+?[?%);O*GFA0`[*83AB,@,1GI7SE_P:Y_&O5O`_P#P4*O/"-O=
MS#1O&_AZZ2YMLYC::WVS12XZ;E`D4'TD->AF=;^TLF>)H7@E=N/>W3]4<N!A
M]0S-8>K[[E:TNJN?T5``#`XI'^X?I38'+Q@GJ1FG/]P_2ORY'WC/X[/VL_\`
MDZGXF?\`8UZI_P"EDM6_"W[97Q@\#^'K/2-%^*GQ'TC2M.B$-K967B6\M[>V
MC'1$C20*JCT``JI^UG_R=1\3/^QKU3_TLEK^DW_@D9\`/`GB7_@FO\%[[4?!
M7A._O;KPM:R37%SI%O++,Q7EF9D))]S7[)FV:T\!@Z52K3YT[*WR/S#+,NJ8
MO$3C3GRVU_'U/YS/^&]/CG_T6;XJ_P#A67__`,=K2\&_MV_'&Y\7:5&_QC^*
M;I)>0J5;Q7?D,"XX.9:_JP_X9C^&W_1/O!/_`(([7_XBA?V9?ANC!E^'_@I6
M4Y!&B6P(/J#LKYN7&.%<6OJR_#_(^@7#-=/6N_Q_S.K\/.9-'@)))**<GOP*
MNTV&%+>,*BA5'0"G5\`W?4^P"O&/^"CW_*//X[_]D]U__P!-UQ7L]>,?\%'O
M^4>?QW_[)[K_`/Z;KBM\+_'AZK\S#$_P9^C_`"/Y&-.N_L%_;S[=WDR+)C.,
MX;.*_:*T_P"#N."TMDC/P5N6*@#/_"2A>@Q_S[FOQ?TJU6^U.VA<D)-*J,1U
M`+8-?O#9?\&F/PDN[1'/Q,^(H+`$_N[/`R,_\\J_6N(9Y6E3_M%-O6UK_/9^
MA^<Y'','&3P+MM>]OEN<'_Q%VP?]$2N?_"F'_P`C4?\`$7=`#_R1*Y_#Q,O_
M`,C5RW[>W_!KNGP5^`&H>*?A!XG\2^,O$&B9N;K1M32$/>6RJ=_V<QHN95X(
M4YW`$#YL`_DOX'MM%M/'NGP^+8M830H[M8]433RD=]%%NP_EB12N\<G##DC'
M&<UY^!RG(<93=3#PO;I>5_NN=N+S+-L-45.M)*_DK??8^P/^"LO_``6C\0?\
M%0='\-Z$WA.U\'>&?#ER]^EJM\;V>[N63RP[N40`*I8!0/XCST`]*_X-;OAS
MJ7B?_@HM>Z_;P2MIGACPS=M>3A3M1IV2*)">@+?.1GJ$;TKZ4_9=_P"#</\`
M9J_:E^&6B^.O"'Q>^(7B7PQJJ"1&MWLHG5@1OBD_<%HW7HRD9!_"OTP_8G_8
M%^&7[`_PVF\-?#G0?[-@O95FO[R>5I[S4I%&`\LC<G&3A1A5R<`9->?F>>X"
MA@)Y?@HM-Z6::M?>]];G=@,HQ=7%QQN*DG;73KVVTL>U"FR]%_WA3@,4V7HO
M^\*_/->I]B]C^1/_`(*+?\G^_&K_`+'C6/\`TMEK^BC_`((`?\HA_@Y_UZZC
M_P"G2\K^=?\`X*+?\G^_&K_L>-8_]+9:_HH_X(`?\HA_@Y_UZZC_`.G2\K]+
MXM_Y%=#UC_Z2?#</?\C&M_V]_P"E(^QJ***_-3[H****`"@G%%8_COQE8?#_
M`,*ZAK6JW<5CIFE6TMW=W$I`2&*-2S,2>P`)HLVTD%TM6?F[_P`'+'[?!_9Z
M_93C^%VAWWE>*?BAN@N2CGS+/2T;]^WJ/-;$0]5,OI7Y\_\`!M]^P@?VI?VS
M$\=ZS9^=X3^%>S4\2)^[N=2))M8\]RC*93_US7UKYD_X*3_MG:A^WI^V%XM^
M(-S).-+NKDV>AVLG'V/3HB5@3'0,5^=O5Y&KZ<_X)L_\%Z[;_@F_^SA:^`M#
M^$%AK-P]Y-J&I:K+KC02ZC<2'`=D$)VA8U1`,GA<]2:_5:>4XG"9/]6PT+U9
M_%Y7_P`EI^)^>3S*A7S+VN(E^[AM\MO\S^CN&+RX=I`QSQ7YS?\`!R1^P9_P
MU#^R"GCS0K%9?%_PK\S408T_>7>FL!]JBXY8IM24#MY;X^\:^8/^(O#6/^B)
M:7_X4<G_`,CU7U/_`(.V]0UFQFMKKX&Z1<6]Q&T4D;^(I"LBL,%2/L_((KYG
M`</YOA<1#$4Z>L7W7W;GO8S.\LQ%&5&=31^3_P`CXP_X(E?M\R?L'_MJZ-?Z
MG>20^"?%X71?$*ECY<44C#RKDCUBD()/78T@[U_499WT=Y#$T;K(LB!U93D,
M",Y![U_&7\0-<TWQ'X[UG4=%TO\`L+2K^]EN++3O.\[[!"SEDA#X&X("%!(!
M.*_HO_X-V?\`@H"O[7/['UOX2UV^\_QM\,$32KSS&S)>66,6MQ[X1?*8]=T6
M3]X5Z_&N6.48YA!=E+]/\G\CS^%\P47+!R?G'^OQ^\_0RBD1@ZY!R#2U^<GV
MC/Y@O^#AG_E+-\2_^N>G?^D,%?LS_P`&Y\:O_P`$B_AAD`XFUCJ/^HM>5^,O
M_!PS_P`I9OB7_P!<]._](8*_9S_@W-_Y1%?#'_KMK'_IVO*_0^(?^1%AO^W?
M_26?$Y1_R.*_S_-'E7_!<3_@AY:?MAZ+J/Q/^&5A::?\4K"+S+NRC`BB\41J
M/NMV6Y`&%?\`C`"L>%(_#7]G;]HGXA_L#_M"6OBCPM=7_AKQ;X=N6@N[.XC:
M,2J&Q):W$1P60D892.V1@@&O[`'0.N#TK\U?^"WG_!$"P_;6T2[^(WPUL;;3
M?BMID&ZX@4B*'Q/$@XC<]!<`9"2'&[A6XP5X.'>(8P7U+':TWHF^GD_+\COS
MG)I2E];P>DUJTNOIYGT=_P`$R?\`@IYX)_X*0?!5=<T64:;XHTQ4CUW099`9
M].E(X9?[\+8.U\<]#@Y%:W_!6?\`Y1K?&W_L4+__`-%&OY@_@#\?_B+^P;^T
M%!XC\,7>H^%?%_ARY:"\M+B-HPX5L26MS"?O*2,,C=",\$`C]W=:_P""FGA3
M_@IM_P`$=OC1JVC-%I?B[2O!M['X@T"1\RV$OD-ET/5X6()5QZ8.#D4\SX>>
M#Q5/$4-:4I+SMJOP[,>79TL70G1JZ5$G\['X>_\`!-?_`)2%?!#_`+'G1_\`
MTMBK^N6W_P!2OTK^1O\`X)K\?\%"O@A_V/.C_P#I;%7]<EO_`*E?I6_'G^\4
MO\+_`#.?@_\`W>?K^@^O./VO_P#DU;XE_P#8IZK_`.DDE>CUYQ^U_P#\FK?$
MO_L4]5_]))*^)P_\2/JCZRI\+/X^=-_X_P"#_?7^=?V:_#W_`)$'0_\`KP@_
M]%K7\96F_P#'_!_OK_.O[-?A[_R(.A_]>$'_`*+6OT#C_P#Y<_\`;W_MI\;P
M=M5]5^IL4445^<GVH5^8'_!U;HUO>_\`!/WP_=2;1/9>,K5HL\DEK:Y4X_"O
MT_K\<_\`@[0^/-C9?"KX:?#6&XCDU34=5F\0W,2L-T4$,;P1DCT9Y7P?6(^A
MKW.&Z<IYG145U/*SR<88&JY=OS/AC_@W3UB?2/\`@K3\.$A)"WD&IP2#LR&P
MG)_50?PK^G,C-?S>_P#!L/\`"^X\<?\`!3BPUM(F:U\':!?W\LFTE5:5!;(#
M]?.8CZ5_2$.17I\:R3QZ\HK\V>?PI&2P3;ZR?Z#!;Q@_<3GVIRQJAR%`/L*6
MBOD#Z5!1110`51\2Z1'X@\/7UA,H:*^@DMW!&?E=2I_0U>H/-`'CG[*OQ8:^
M\.V?A'69676](A,$+RGF^CBRC`'O)&5*L.IVAOXN/8\XKY2_:+\(MX-^*-ZJ
M-)##J+#5]/EB.QH)<@2[&'(99/GS_P!-A[BMCX7_`+;#>'BNG^-HGEB4[8]7
MM8LG'_3:(#@_[29!_NK0!]*T5F^%O%^E^-]*CO\`2+^SU*RE&4GMIEE1_H03
M6E0`4444`%%%%`!1110`4444`%%%%`!1110`4C*'&",BEHH`XOXF_L^>$/BU
M"QUO1;:>Y`PEW$/)N8_<2+AOP)(]C7@/CS]C_6_AB\E[H,LWB32E^9H2@%_`
M/]U0%F&.RA6_V6-?65!&10!\F?!GQDGA'Q?IFLPRAK&5A8WY7H(9&QN8>L<@
M!.?N@R#C)KZS'3TKQ[X_?`R*^M+W7M(@;[9)&W]I6D(P-1C*X9U':91R"/O`
M;3GY2O;_``4\7_\`"=_"[0M4:59Y;FS7SI%Z/*OR2$?\#5J`.JILAQ&QR!@=
M3VIU)(F]&7U&*`]3^5[_`(+FZ=)IG_!5WXS)(.9-6AF7W5[2!P?R-?K=_P`&
MZ/[1/@/X<?\`!,7P[IFO^-?".B:C'K.I.UK?ZO;VTRJ;AB"4=@P!'/2O&O\`
M@X+_`.",'Q!^/?QT7XR?"G2?^$GDU2QBM=>T:W9$O%FA&Q)XE8CS`T852H^8
M&,$`[N/RDU;_`()^?';0;TV]W\'?B7!<)U1_#=X"/_(=?JL8X7-<KI47547%
M1OMNE;9M'YZYXC+\PJ5HTW)2O]S=_,_JJ'[8WPI(_P"2F?#W_P`*&U_^+H_X
M;%^%'_13?A[_`.%#:_\`Q=?RE_\`#"?QL/\`S2/XD?\`A.7?_P`;H_X82^-G
M_1(_B1_X3EW_`/&Z\W_4W!_]!*^Y?YG?_K/B?^@=_C_D?U9M^V-\*?\`HIGP
M]/\`W,-I_P#%U_.%_P`%]?&>D^/O^"HOC_5-#U33]8TVX@T\175C<)<0R8LH
M0<.I*G!R.#7A/_#"?QMZ?\*C^)'_`(3EW_\`&Z[OX+_\$BOVD/CKXEM=.TGX
M1^,;!;EPC7NL6$FFV<`)P6:68*,#T&3Z`UZF49/A,KJ2Q"Q">ENB_4\_,LSQ
M./IJC[%K6_5_H?LE_P`&K%E+;?\`!.C6)9$VQW'C"],9/\0$%L"?SR/PK],3
M7@7_``30_8X@_8-_9`\)_#9+J*_O=)@>?4[N($)=WDSF29U!YV[FVKGG:BU[
M[7YQF^)C7QM6M#9R=C[?+Z+I8:%.6Z2/S!_X.LM*EOOV`?#=R@S#9>,;4R'!
MXW6UP!7YC_\`!O+XVT?X<_\`!4CP=JNO:KINC:9#IFJK)=7UREO"A:RE"@NY
M"@DG`YK]]_\`@IG^Q/!^WW^QUXN^'37<.GZEJ$27>E7<L>Y+:]@;S(2W<*2"
MC$<A7;%?S<_&7_@DA^T;\#?$-U8:O\(_&5XMJQ47NE:?)J-G,,D;EEA#+@^A
MP?4"OM^&,1AZ^5U,#5FHR=]^S/D\^H5J6.AC(0;2M]Z/Z>_^&Q?A1_T4SX>_
M^%#:_P#Q='_#8OPH_P"BF_#W_P`*&U_^+K^4O_AA+XV?]$C^)'_A.7?_`,;H
M_P"&$OC9_P!$C^)'_A.7?_QNL_\`4W!_]!*^Y?YFO^LV)_Z!W^/^1_5I_P`-
MB_"C_HIOP]_\*&U_^+KQS_@H5^U3\-/$?["GQDL;#XA^![V]O/!6K006]OKE
MM+),[6<H554/DL2<`#K7\UW_``PE\;/^B1_$C_PG+O\`^-U);?L$_&^ZE6./
MX0?$J1VX"KX<NR3_`.0ZNEPAA(5(S^LK1WV73YD5.)<3*+C[!J_K_D>=>"=,
M?6/&&D6D7S2W=[#"@'JTB@?SK^SV,YC7Z5_/'_P2-_X(1_%SQW^TMX4\:?$[
MPCJ'@CP/X3U"'5I(-8C\B\U:2%M\<*0'YU4NJEF<#"YQDGC^AU/NCZ5YW&N/
MHXBM3IT9*7*G=KSM_D=G"N#J4:4Y5%;F>E^R%K\J?^#LW_DRSP!_V.*_^D=Q
M7ZK5^97_``=!_"/Q7\9/V1O`^G>$O#>N>)KZV\5K<2V^EV4EW+'']DG7<RQJ
M2!D@9/<UX?#TDLQHN3MK^C/7SF+E@JBCJ['@?_!H)_Q\_M`_7PY_[E:_;&OQ
MW_X-5O@9XV^"-S\=/^$P\(>)?"_]I_V`;3^U=.FL_M/E_P!I[]GF*-VW>F<=
M-P]:_8BMN)YQEF=5Q=UI^2,.'H2A@*<9*SU_-GS9_P`%2/\`@GQH/_!1/]EC
M6/!]\(K7Q#:YOO#NILHW:?>J#MYZ^6XRCCNK9Z@5^,O_``2)_P""(/CGXP?M
MH-_PN'P5KWAWP3\.[H7&I1ZE9200Z[<1R$1VT3,`LL3,A9V3(*#&?G%?T6XY
MI`,5E@<_Q6%P\\-3VE]Z[V_KS-L5E%#$5X5ZBUC]S]2*QL8].MDAA54BC`5%
M4`!0!@``=@*X3]J__DV7XB?]BOJ?_I+)7H-<%^U%97&J?LZ>/+2T@ENKJ[\.
M:C###&I9Y7:VD"JH')).``/6O)HV]I%ONCT9_"S^0_X*?\EC\)?]ABS_`/1Z
M5_97%_JE^E?R3?!_]A[XS6'Q9\+SS_"CXBPPPZO:.\C^'KM511.A))*8``R?
MPK^MB!MT*\$''0]17W/'5:%2I2<))[[/T/D^%*,X4ZJFFO>0^OR/_P"#N/\`
MY-H^$O\`V-%Q_P"DC5^N%?EI_P`'2_P;\6_&?]GKX7V?A'PQK_B>ZLO$<\\\
M6E6$MV\*&V90S",$@9XR:^=X<G&.94G)V5W^3/:SR,I8&HHJ[M^J/SR_X-L/
M%>E^"_\`@II87NL:GI^DV8\-ZDAN+RX2"(,1'@;F(&3Z9K^B2+]HOX>B-1_P
MG?@W.!_S&K;_`.+K^34?L)_&P'_DD7Q(/_<N7?\`\;H_X82^-G_1(_B1_P"$
MY=__`!NON\YR+#YA7]NZZCHELNGS/D,KS?$8.A[!46];]5O\C^LS_AHSX>_]
M#WX-_P#!U;?_`!=))^T;\/E1B/'?@W(&?^0U;?\`Q=?R:?\`#"7QL_Z)'\2/
M_"<N_P#XW1_PPE\;/^B1_$C_`,)R[_\`C=>2N#,-_P!!*^Y?YGH_ZS8G_H'?
MX_Y'ZJ_\'3/[9G@3XE_"3P#\-_#'BG1/$.N6FNR:UJ$6F7D=TMC''`\2"1D)
M"LQE;"YSA2<=,_)O_!M5:2S_`/!5;PQ(BDK;:+J<CG^ZOV<KG\V%>!?#O_@E
MI^T5\4]4BM-'^#/Q!9Y6"^9=:/-9P)G^]+,%11]2*_;#_@A)_P`$8-5_X)_+
MJWCWXA3V,WQ$\16(L(K&U830Z):,ZR.ADZ/,[*FXKPH3`)R37HXVK@LKRF>"
MA54I236EKN_ET./#4\3F&8QQ,H<J5OP/TEMQ^Z&.F.*<_P!P_2DBC\J-5ZX%
M$S;(7/H":_+EN??,_CM_:S_Y.I^)G_8UZI_Z62U_2C_P2*^.?@GP]_P36^"U
ME?\`C#PM8WEMX6M(YH+C58(I8F"\AE9P0?8U_/\`?M0?L2_&/6OVEOB'>6?P
MK^(5U:W?B;4IX98O#]TZ2HUW*592$P5(P01UKA?^&$_C;_T2/XD?^$Y=_P#Q
MNOV#,\OP^8X2E2E64>6SZ/I;NC\UR_%5\#7G-4G*^G5=?0_K,_X:,^'I_P"9
M[\&_^#JV_P#BZ/\`AHOX>_\`0]^#?_!U;?\`Q=?R9G]A/XV$_P#)(_B1_P"$
MY=__`!NC_AA+XV?]$C^)'_A.7?\`\;KY[_4W#?\`02ON7^9['^L^)_Z!W^/^
M1_68?VB_AZ/^9[\&_P#@ZMO_`(NI;+X_>!-3O8;:V\:^$KBXN'$<446L6[O(
MQ.`J@/DDG@`5_)=_PPE\;/\`HD?Q(_\`"<N__C=>F?L7_L6_&#PW^UY\+M0U
M#X6_$"RL;'Q9IEQ<3SZ!=1QPQI=1LSLQ3`4`$DGI6=7@_#0@Y+$IV79?YFE+
MB3$RFHN@]7Y_Y']6(.37C/\`P4>_Y1Y_'?\`[)[K_P#Z;KBO9DY4'CIVKR+_
M`(*!Z+>>)?V#OC5ING6ES?ZAJ/@36[6UMK>(RS7$KV$ZHB*.68L0`!U)KXO"
MM>V@_-'U.)3]E)>3_(_D4\/_`/(=L?\`KX3_`-#%?V?Z/_R#XA_L+_Z"*_D6
MT/\`85^-4.MV3-\)?B,JK.A8GP[=@*-PY/[NOZY]%8MI\>5*G8N0?H*^XXYK
M4YJBH-/XMOD?)\)4IPC4YU:[7ZEB:U6<8.?P[U^,'_!P!_P1)_M@:Q\=?A'H
MS"[3==>+-!M(L_:`,EKZ!!_'CF1`.>7'(;/[1U%=VJWENT;A2K\$$9!'I7Q^
M6YE5P-95J/S7='TV.P-/%TG2J_\`!7H?RM?\$M/^"IGC'_@FA\9%O;$S:SX'
MUB9%U_0)),1W*CCSXL\).@Z-T;[K<8Q_39^S3^TMX/\`VM/@YI/CKP/J]OK.
M@:Q'NCECX>%\#=%(O5)%/#*>0:_&/_@NO_P0IU'P3XQNOBO\$O#]WJ>C:S/G
M7/#6F6QDEL+ASS<6\2<M$Y(W(!E&.1\I^7Y]_P""7GQ6_:>_X)K?&!=4TSX2
M?$[6?!NJR(NO^'WT&\6.]C'_`"UC)CQ'.H)P^.>A!!X^WS7!X3-Z"QV&DHU.
MJ;M?R?GYGRN7XC$Y=7^J5TY0Z-7T_P"`?TN#FFR]%_WA7-_!_P"*EC\:?AWI
M7B73;74[*TU6W6=;?4;1[2[MR>L<L3@,CJ<@@]QW'-=#=2>6JG&?F]<5^<N+
M3Y7NC[6]U='\B_\`P45&?V_OC5_V/&L?^ELM?O;_`,$+OVE_A]X"_P""5'PD
MTG6O'7@W2-3M;:_$UI>ZS;P3P[M2NV&Y&8$9!!Y'0BOQ<_;X_8Q^+_BG]N#X
MO:GIOPN\?WVGZAXQU6XMKBWT&ZEBGC>[D975@A#*00017DO_``PK\;=N/^%1
M_$C_`,)R[_\`C=?L&/P6&S'!4:4ZJC9)]'TMW/S;"XJO@L94JQI.5VUU6[]#
M^K/_`(;%^%'_`$4WX>_^%#:__%T?\-B_"C_HIOP]_P#"AM?_`(NOY2_^&$OC
M9_T2/XD?^$Y=_P#QNC_AA+XV?]$C^)'_`(3EW_\`&Z\+_4W!_P#02ON7^9Z_
M^L^)_P"@=_C_`)']6G_#8OPH_P"BF_#W_P`*&U_^+K7\#_M"^!_B7KO]F^'O
M&7A37K_RS+]FT[58+J8(."VU&)P"1SC'-?R:?\,)?&S_`*)'\2/_``G+O_XW
M7Z`_\&U_[,GQ&^$/_!1B75O%7@/QAX;TQO"=_;B[U+2)[6'S&EMB$WNH&XA3
MQ[5PYCPMAL/AIUH5U)Q5[::_B=.#S_$5J\:4J+2;WU_R/W[+X4FORI_X.=_V
M_C\(/V?=-^#6@7HC\1?$/,VKF)L26FEQMRAYR#-*`ONL<@[U^H_BCQ'#X4\/
MWVHW"3/!86[W$@AC,DC*JDD*B@ECQP`,FOY<_P!N[P/^T)^W'^U7XL^(VJ_"
M3XF1?V]>$:?:OX>N\65FGR6\(^3^&,+GU8L>]</">!IUL7[:LTHPUU[]/\SL
MS_%U*>&]G25Y2TVZ&S_P1J_X)1-_P4Z^*'B2WUG4]6\.^#?"UBLEWJ-C'&TT
MEU*P$4"[P5^Z)')QT0>HK]%Q_P`&E/PJ(_Y*C\0?QBLQ_P"TZ^P_^".G[$47
M["'[$GA;PM<VJP^)]6@76?$4A`WM?3JK-$3Z1+MB'_7//>OJJM\UXIQCQ4_J
MM1J"T6VMNOS,LNX?PT:$?;0O+K<_)/\`XA*/A5_T5'X@_P#?JR_^-T?\0E'P
MJ_Z*C\0?^_5E_P#&Z_6RBO-_UGS7_G\_P_R.W^P\%_S[1^%'_!0G_@V>T3]F
M?]E'Q1X]^'OC#Q7XIUSPM"-0GTV_AM]D]HA_?LOEJ#N1#O\`<(PQG%?"?_!*
M;]N.\_8%_;+\,^,C)+_PCEW(-+\16XSB:PF8!V([M&VV5?=,=Z_JYU?1X-<T
MV>SNHXY[:YC:*:-UW+(C`JRD>A!(K^8/_@I1_P`$E/B-^S;^V1XR\/>"O`?B
M_P`2>#);K^T-#O-+TF>[A%K.2ZPED5ANB.Z,YY.S/>OJ^'<Y>/IU,%F$DW).
MS?GT^6Y\]G.5_5*D,3@XVLUMY?U8_IW\+:Y9^)O#ECJ.GW,-W8W\"7%O/$VY
M)HW&Y64]P0015^OSQ_X-X/C=\0M>_94;X;?$WPKXK\/ZW\.Y%M],N=8TV>U%
M_ISY,2JTBC<T3!D('1/+]Z_0UCM4G&<5\#CL*\-7E1;O9GV&'K>VI1J;7/Y@
MO^#AG_E+-\2_^N>G?^D,%?LY_P`&YO\`RB*^&/\`UVUC_P!.]Y7Y1_\`!=_]
ME#XH?$__`(*@_$/6?#GPZ\;:[I%TE@(;VPT6XN()2ME"K;71"IP01U[5^N'_
M``0#\#:Y\-/^"67PYT3Q'H^I:#K%I+JQGLK^V>WN(=VJ73KN1P&&58$9'0BO
MML_K4Y9+AX1DFUR_^DL^3RBE-9M6FUH[_FC[.ILD8DC93D!ACBG45\`?9GYN
M_P#!;C_@B-IG[;_ARX\?_#RTM],^+&F0$R1KMCA\2QJ,B*4\!9AC"2?\!;C!
M7\%/AG\4_&G[(/Q)\0V\,-WH^J3V%_X9U_2KR%XQ/!-&T,]O-&<$%2=PS]UT
M4CI7]AI&:_.;_@M9_P`$2M(_;E\)7'CKP'!9Z3\6M+A+9$8CA\1QJ/\`4S'^
M&4#A)#[*W!ROVG#G$:HKZIC=8/1/M_P/R/EL[R5U)?6<+I-;^?IY_F?AC_P3
M7_Y2%_!#_L>='_\`2V*OZY+?_4K]*_EJ_8%_8D^,7@+]OKX17>L_"[Q]IMGI
M'C?2Y+RXN-#N4AMDCO(][L^S:%`!);.,"OZE+4[H%/'2M..*L*E>E*#3]WIZ
MD<)TIPH5%-6U_0DKSC]K_P#Y-6^)?_8IZK_Z225Z/7GG[6-C<:M^S/\`$*SL
M[>:[N[SPQJ<$$,2EGE=K60*J@<DDX``]:^,H-*I&_=?F?4U/A9_'KI[!+Z`G
MH'7/L,U_7;X$_:_^%EMX)T>*3XD^`(WCLH597\06H92(UX(W\&OY8O\`AA/X
MV`<?"/XD?^$Y=_\`QND/["?QMS_R2/XD?^$Y=_\`QNOUW/<LPV9\G-64>6_9
M[V\_(_-\IQV(P#FE2<K^JV^1_5H?VQOA2!_R4SX>_P#A0VO_`,76-KW_``4$
M^!_A>"634/C'\++-8@2QF\4V28_.6OY9/^&$OC9_T2/XD?\`A.7?_P`;JWH_
M_!/;X[Z]<>3:?!SXF7$AP-J>&[LG_P!%U\__`*FX+KB?R_S/7?$V*_Y\?G_D
M?O1^UY_P<B?`#X`^&KR+P?K)^)_B949;>TT>-ULM_8R73`($]=F\^@K\"/VP
MOVM_&/[<?[0.L_$+QI<I/J^L2*D-M#E;>P@7B.WA4DD(HZ9)))))))->\_!+
M_@@7^U'\:K^!!\.;CPK9RGYKOQ%<QV*1#/WC'DR_DF:_5+_@FE_P;@^!?V4?
M$FG>,?B5JL'Q%\::>XN+2U%OLTC2Y1R'5&RTSJ<$.^`.R`@&NRC5R?)8.5.?
MM*C7>[]--$<]2GF>:24*L>2'I_3;-?\`X-Q_^"=^H_L?_LS7WC3Q78R6/C+X
MFO%=-;2KMET_3XP?L\3CJ'8O)(P]'0'E37Z/CI]*;!`((E0=%Z4^OSO'8VIB
MZ\L15WE^'9?<?:8/"PPU%48;(****Y3H"BBB@`HHHH`X#]HOX5R?%#P%(MDJ
M#6=+8W5@Q./,<##1$]A(N5SV)5OX:^)/$\HFB9BCHPRK*Z[60CAE([$'(([$
M&OT9<90@9YXXKYC_`&R_V;[EGNO%_AVV:;>-^K64:Y9\#'VB,#JP``=1R0-P
M&<[@#Y&C\:ZQ\.M;;4=`U74-&OLC?-:3-$90.@<`X<>S`BO0_!O_``5:\<^`
MT6'Q!INE>*;=``7_`./.Y(]2R@H3_P!LQ7E'BQ@X9E(96Y!!R#7F?B_HW^?6
M@#[^\#?\%D?A7K;QQ:]#K_ABXQAFGMA<6X^C1DL?Q05[)X(_;>^$GQ%"?V3\
M0?#$[R8`CEO5MY,GMLDVM^E?B5XLZL,G!'/-<@G$AQ@<]J`/Z*]+\1Z?KENL
MME?6EY$_W7@F616^A!P:N!P1WK^>3P[XAU#0V#V5]>6;CHT$[1L/Q4BO0/#?
M[3?Q(\/*HL?'_C6U1?X(];N0O_?._'Z4`?NV&ST!I:_%G1?V[OC#IZ!4^(GB
M5U7IYMQYO_H0-=-8_P#!1?XTQ(`/'>H$#GY[:V<_3F.@#]@**^%?^";7[7/Q
M$^.WQSO=(\5>(Y=7TZ'2);E8FM+>+$BR1*&RB*>`QXS7W50`4444`%%%%`!1
M110`4444`!&:Q_!'@>Q^'^D26&FH8K1[FXNA&3D1M-*TK!?1=SG`[#BM9Y%C
M(R<9Z5E^#_'.D^/]/GN]&O8K^VMKNXL)9(P=J3P2M#-'R!RDB.I]U-.SM<+F
MM0>1112`0J">@)%!4$Y(!-+118$)L&>@H\M?04M%`[B;!Z#\J"@(Q@&EHI6$
M(%`Z`>E+110DEL`$9%-$8`Z#&.G:G44-)[@)L'H*/+7T%+13'<3RU]!1L'H/
MRI:*/4+C3&,?=7\J<!@444K(+A2%<]<9I:*+"L-\I?[J_E3J**86"BBB@`I"
M`>P-+10#0FP>@I0`HP,`444@"D**QY`/X4M%,!-@]!1Y:^@I:*-1W$\M?04;
M!Z#\J6B@5QIC&1@#BE"!6)`'-+10&H4$9%%%`#1&!C@8'M2[!Z"EHI+0!-@S
MT%&P>@I:0L!3N%P*`]A08U/\(_*ESFB@$P`P.*1EW#!`(]Z6B@!OE*.<#-*J
M[1VI:*'KN`4444)@-,8;.0.:41@#&!2T4!=B*@4D@`$T$;AS2T4/4$-$:C^%
M?RI=@'84M%+Y@)L`["C8/04M%/4=Q-@ST%&P9S@?E2T4"8FT>@I#&.>!D^U.
MHH!:"*@3H`/H*6BBBW8`HHHH`*:(5!S@<^U.HH`;Y2[@<#(]J<1GTHHI"2L)
ML'H/RH"@'(`I:*=AA1110`4A7=U`/UI:*6C`;Y8]!^5.`P.***+"L%(5![`T
MM%,;5Q-@]!^5&P>@I:*`$V`=A1M`["EHH`:8PPY`/U&:41JIR`,^N*6BBP:+
M0****`"BBB@`HHHH`****`"D==P-+10!\D?M@?L'3:\;OQ)X%M_])D+37FC+
MA5F/4O!GA6/4IG#=1@DAO@/QS:S6-U/;W$,MO<0.T<L,L;1R1,."K*>5([@\
MBOVSKQ;]J']A[P=^TS9/<7L3:1X@5=L.JV:`2GT65?NR+['!]&%`'XP>+.&-
M<<O^L/UKZ>_:R_8`^(G[.YN;NZTN36]`A)(U73D:2%5]9%QNB_X%QZ$U\PH<
MR-]:`-&Q^Y6I9]*R['[E:EGTH`T[/^M:L'W1]*RK/^M:L'W1]*`/KO\`X(]_
M\G,:C_V`)_\`T=!7Z8U^9W_!'O\`Y.8U'_L`3_\`HZ"OTQH`****`"BBB@`H
MHHH`*;)((U))`P,]:Y3XK?'#PM\$-&;4?%>O:5H-ET22\N%C,S8SM1?O.WLH
M)/I7P7^V+_P6BNIK&YTCX5:9)9EU,9\0:K#AU[9@MFYSZ/+C'_/,UVX/+Z^)
MDHTH_/H9U*L8?$>R?\%5/^"DFD_L8_"NZTC1[N"]^(VMVKKIMHAW_P!FHP*_
M:YL?=4<[%/+L..`Q'JO_``3X^%EY\'?V.OA[HFI^<=731HKS4VE'[Q[RXS<7
M!8]V\V1\GO7XW_L>_`O5OVW/VX=`L-9N+S65N+W^V_$5[=.99);:!U=]['KO
M8I$!V\P8&!7[[0J%B0*`%"@`#H*]+.,)3P5.&$@[R?O2?X+]3GP\W4FZC]%^
MHZBBBO`.PJZOJL.BV$]W<S1P6MK$TLLCG"QJH)+$]@`#7SS_`,/=/V:/^BX?
M#OG_`*C$5>Q_'7_DC7BW_L#7?_HF2OR=_P"#;/\`8G^$G[17[$?B#6_'7P[\
M(^+-6M_%=Q:17>JZ;'<S)$MO;L$#,#A068X]Z]7`X+#U,+4Q.(O:+2LK=;]_
M0\[$XBJJ\*%*UVF];]+=O4_2[X4?M_\`P3^-NKQ:?X6^+7P\US4)SMBL[;7K
M9KF4_P"S%O#G\!7L`D5NC`Y]Z_./_@JI_P`$?OV;-)_8[\?>-;+PGH?PVU[P
MGH\^IZ=K&CG["%N8T+11/&#Y;B1PL>-N[YQM(.*ZW_@WB^/?B_X__P#!.?0;
M[QG>76IWNB:I=Z19WUTQ::\M82OEEFSEBF]H\GDB,9Y%.M@:+PCQ>'D^5.S3
M2ZJZM9ZCIXJI&O\`5ZR5VKIKUMJGJ?>%%&:*\D]!GGWQ1_:>\"?!+QAX=T'Q
M;XMT3P_J_BZ8V^BV=]<K%-JD@9$*0J>7;=)&,#NZ^M>@1MN0$]Z_)_\`X+W?
M\I%?V(O^QJE_]+]+K]7X_N"N_$X-4J%*LG\:;]+.QQX?$NI6J4VOA:7X)_J5
M];U>W\/Z-=W]W-';6EC"]Q-+(<)$B*69B>P`!)^E<K\"OV@_!G[2G@V3Q#X$
M\3Z-XMT2.Y:T:^TRX6>%9E"LT98<;@&4D?[0H_:/X_9X\>_]B[J'_I-)7P3_
M`,&K'_*-+5/^QVU#_P!)K.E2PBEA9XB^L6E;UO\`Y!4Q+CB8T+;IO[K?YGZ5
M4445PG8%9GC'QEI7P_\`#&H:SK>HV>DZ5I=N]W>7=U*L4-M$BEFD=F(`4`$D
MGH*T9I/*B9O[HS7Y@?\`!>+]H?7_`(]^.O`?[(?PTN"WBSXHW4,OB*6(%AIV
MGAR563'16V/(_P#TSB]'KLP&$>)KJE>RZOLENSFQ>)5"DYO5[)=V]D?H3\"_
MVCO`W[2?A>?6_`GBS0?%ND6\YM9+O3+M)XXY0`6C8J>&`*G![$>M=QUK\;/V
M?]";_@A%_P`%4+'X<RZC>'X&_'2T@32[V]DREEJ$86,,[G"AED<JW^Q<1$_=
MK]DHSE!]*TS+!1P\XNG+FA)7B^_?YID8/$NK%J:M*+LU_71]!:***\\[#,\7
M^*K+P1X=OM6U.[@L--TRW>ZN[F8[8[>)%+.['H%"@DGMBO`O^'NO[-&!_P`7
MP^'7/_49BKM_V[?^3,?BS_V)NK?^DDE?GC_P;S_L+_!W]H#_`()V6/B#QK\-
M?!GBC7&UZ_MS?:EID5Q.T:,FU2S`G`R<5ZV$P>&EA)XK$MVBTK*W5>9YV(KU
M57C0I6U3=W?I;MZGZ#?"C]O[X)_&W6(]/\+?%KX>:YJ$[;8K.UUZV:ZD/^S%
MO#G\%KV`2*>C`_C7YQ?\%6/^"/\`^S9I'['/C[QM9>$]#^&NO^$M(GU/3=8T
M<_80+F--T43Q@^6XDD"Q_=W?.-I!Q78_\&\WQX\8_'__`()R^']0\:75WJ=Y
MH^IW>DV5_=,6FO+6$CRV9B<N5+-'N/41C/-*O@:+PKQ>';Y4[--+JKJUGJ%+
M%U%7^KUDKM737K;KJ?=M%%*.M>4CT6>9?'S]KSX;_LO'3C\0O&_AWP<NK>9]
MB.JW2VXNC'C?LW'G;N7./45V7P^^(>B?%3P;IOB#P[JVGZWHNKPBXL[ZRF66
M"ZC/1T8$@@U^37_!SSX)M?B5\7?V8O#EZ\L5GK_B"ZTV=XR`Z1S3V4;%<]P&
M.*ZW_@@U\9]<_9=^./Q#_8Z^(=RRZUX#O;C4?"LDIP+VR<^:Z1YZJ5=;A0.T
MLG]VO?EDZEET<73?O:MKR3M=>AY"S)K&/#S7NZ)/S:O9^NMC]4B0!D\`5P_Q
MT_:/\#?LU>%8=<\>>*]"\)Z1<3BUBN]3NTMXY9B&8(I8\MA6./0$UVTW,3?0
MU^&'_!53Q=J7_!6#]LCQ[X3T"]G_`.%4_LR^%]4U;4KNV;]U=:DD+$KN'RDM
M-&(E_P!F&8CK7'E6`6*J\LW:*U;[=OFV=./Q?U>G>*O)Z)?UT2/VD^"_QP\*
M?M"^"(/$O@KQ#I7B?0+EWBBO].G$\$CHVUE##@D$8-=;7P%_P;0_\HIO"W_8
M9U3_`-*GK[]KGQ^&6'Q$Z"=U%M?<;82LZU"%5JW,D_O0444CL$4D]JXWL=!A
M?$KXD:)\)/!>H>(O$>K6&AZ'I4)GO+^]F6*WM8P0"SLQ``Y[UF?!'X[^$OVB
M?!47B/P5XET;Q5H<TCPK>Z;<+/"9$(#KN4D9!ZBOS:_X+4?%[6/VY_VIOAW^
MQMX"NI(SK-[%K'CF\MSD6-H@\Q(W(XPJ!I2#U;R!WKG?V'-3F_X(R_\`!577
M_P!GK5+BZ'PC^,)74O!-W=R%DM;MN(XBYX+'#6[=RZPGC=7O0R>^%]IS?O&N
M91[Q3M?UZ^AY4\Q<:W+;W$^5O^]V].GJ?KQ13()!*@;UI]>$>JPI&=4ZD#ZF
MEKYV_P""H_[<EE_P3W_9#UWXA3017NJHZ:=HEG(2%O+^8-Y:G!^ZJJ\C#NL;
M8P>:UH49UJD:5-7;T1G5J1IP=26RU/6OC#\??!/P`\+MK/C7Q;X<\)Z8N0+G
M5=0BM$<@9VJ78;F]AD^U?.%U_P`%W/V4[/5S9/\`&'0C*&V[TL[MXL_]=!$5
MQ[YQ7R__`,$Y?^"3$W[;>E:;^T'^U;J&J?$'Q/XQB74]'\.WMPZ:;I=F_P`T
M)>%<##*0RQ#"*K#*L<X_06V_83^#%IX>&DQ?"GX=KIP3RO(_X1RSVE?3/EY_
M6O4J4,!AY>RJ2E.2WY;)7\KW;M\CAIU<55CSP2BGM>[;];6L;GP*_:@^'G[2
MWA]M3\!^-?#/BVTCQYK:7J,5PT!/02*IW(?9@#7>U\6>$O\`@AK\(OA'^U_H
M7Q;^'M[XH^'5QI6Y[G0]`OOL^FZC(2"`ZL&98CSNB4A&XX7!S]I@8KS\7&@I
MKZO)M/NK-/MV9UT)U6K5DD_)A3+AS'"S#.1Z4^FSG$1KFM<W9\[ZG_P5B_9P
MT74KBSO/C5\/;>ZM)6@FB?5X@T;J=K*1V((-0?\`#W;]F?\`Z+A\.O\`P<15
M^='_``0`_9*^&?[2WC7]HN?Q_P"!?"_B^72O%RI9OJUA'=-;J\ER6"EAP"5'
M3TK])Q_P2H_9P_Z(E\-?_!%!_P#$U[^.P&7X6LZ$^=M6VY>U^IY.&Q&*Q%-5
M8**3OWZ.QZ!\`/VI?A_^U%I6HW_P_P#&&@>,++2IA;W<VE72W"6\A&X(Q!X)
M'->@UPGP._9F\`_LTZ=?V7@'PCH'A&SU.59[J#2K)+:.>11M#,%&"0.,UW=>
M)6=/G?LK\O2YZD.;E]^U_(*X'X]_M->!/V8M$LM3\?>+-"\(:=J$_P!FMKC5
M+I;>.>7:6V*6X)V@G'M7?5^4?_!V?_R:+\-/^QN/_I)+75EN$6)Q,*$G92.;
M'8ET*$JR5['ZKVLQG4D]/IBDU"[6QM'F=E1(U+,QZ*`,DT67^K/UJAXX_P"1
M0U/_`*]I/_0#7$E=V.E2O&YR_P`"?VE_`W[2VD7VH>`_%>A^+;'3+HV5W<:9
M<K/';S!0WEL5Z-M*G'O7>U^5G_!J9_R:]\5O^QYD_P#22"OU3KMS/!K"XJ>'
MB[J/7Y)G/@L0Z]"-5JUPKQOXT_M\_![]G+QF/#WCSXE>$?"FM-;I=BRU*_2W
MF,3DA7VMSM)5AGV->R5Y-\7?V%OA!\?O%YU_QO\`#GP?XKUKR$MA>ZGID=Q,
ML2%BJ;F!X!9L#WKFH*CS_O[\OE:_XFM;VG+^ZM?SO;\#B/\`A[K^S/\`]%P^
M'7_@YBH;_@KI^S3T'QP^'0/_`&&(C7YY_P#!R=^QC\*?V=/V4?`6J>!/A]X2
M\)ZA>^-H+*XN=+TR*VDG@:SNW,;,HR5W(IQZ@5^A/@W_`()8_LZ7?A#2I9O@
MM\.))9+2)G=M#A9F)09))'6O9J8/+84(5WS^]?3W>EO\SS:>(Q4J\Z/N^[;O
MU/9_@O\`&_PG^T-X$A\3>"O$&E^)]`N)9(8K_3YA-!(R-M<!AP2#P?>NLKE_
MA!\%O"OP"\%Q^'/!F@:5X:T*&5YH[#3K=;>WC=SER$7@$GD^YKJ*\2?)S/V>
MW2^YZL;V][<*X&U_:<\!7GQXG^&<?B_07\>VT'VJ70!<K]O2'8)-YCZ@;&5L
M^A%=]7Y.^#/^5K_Q/_V*`_\`35;5V8'"*O[2[MRQ<ONM_F<V*Q+I.%E?FDE]
MY^L5%%%<!UA5'7_$=CX9TB>_U"^L]/LK13)/<7,RQ10H.I9F(`'N33/%/B6U
M\'^'[S4[^9+>QT^WDN;B9SA8HT4LS'V`!/X5^-OP;T;QM_P<7_M.>)]=\5:Y
MK/AC]F?P%J/V6PT+3YC;MK4HPR*[=Y"FUY&(.P.JK@G=7?@,#[=2JU)<M.&[
M_))=6SCQ.+]DU"*O*6R_7R1]\?$#_@M?^S!\,]7DL=2^,OA.>YB;8W]G/)J,
M8/\`OVZ2*?P-=I^S[_P4L^!O[4>KQZ?X(^*/A'6=3DQLT_[6+>\E_P!V&7;(
MWX*<4_X2_P#!-;X#_!CPU#IOAWX4>!;2WB0)YD^CPW5Q(!W>68-(Q/<LQ->1
M_M@?\$)O@)^U5:Q7-EX?C^&_BFVF2:#7/"D4=A.N&R0T:CRGR.A*[@>0>QW4
M<L;Y;SCYNS_!?YLSE]=BN:T7Y:K\?^`?9ZR*_P!U@<>AI:Y[X5_#Z/X6?#_2
M/#\6IZQK$>CV<5FM[JMS]IO;H(N`\TI`WN>[8&370UY35FTCO3NKA03@45D>
M/_&VE_#?P1J^OZU>P:=I&B6<M]>W4QQ';PQH7=V/H%4G\*(IMV0_4XWXP_M<
M_#;X#>,=$\/^+_'?A?PUK7B,@:98ZA?)#/>DN$&Q2<D%B!GUKT=)%D^ZRMCT
M.:_!OPY^QWXM_P""\T_Q\_:"OY-1TZ.T0Z1\+[-I/+5GMG\T(W/(V`(Q''FW
M#M_!7Z)_\$-?V]9OVV?V1;>T\0S,OQ#^'A30/$<,_%Q(\8*Q7+@\YD53NX'[
MQ)*]K'Y1&A0]I3E>46E-?RMJ_P!W3U/*PF8NM4Y91M&7POO;?_/T/M.BBBO$
M/5$8X4FN`^(W[3O@/X2>/_#_`(3\2>+]!T3Q+XK81Z/IUY<K%<:D^X)B)#RQ
MW$#CN17?R?ZMOI7Y,_\`!:'_`)3(?L;?]A5/_3A#7?EF#6*KNE)VT;^Y7./'
M8ET*?M$KZI?>TOU/UF7.T9ZXI:**X#L"BB@]*`,KQ?XTTGP'H%SJVLZII^D:
M58(9+J\O+A((+=!U9W<A5`]20*^6O$G_``7-_97\+ZZ^GW/QC\.2SH^PO:0W
M-W!G/_/2*-D/U#8KXM_X.*_'5QXF_;)_9[^%WC'6]0\/_!KQ!<0WNNS1S&&&
M=S>"*7S&Z?NXMI&<[?.)K]&OA7^P'\!?"?PUT_2_#WPP^'CZ%+:H(F71K:Z%
MU&RC#&5U9I-P.=Q8YSG->U]2P]'#TZ^(YFYW:4;))+N[/4\SZU6JU9TZ%ERV
M3O>_?96T.P^`'[4_P[_:B\-'5?A]XU\-^+[*,[9FTR]CF>W/82(#OC.,<,`:
M]"KYP_9V_P""4?P4_95_:*UKXG>!?#,F@^(-:M_LQMX+N1;"S4_?\F`':N\X
M)SD#'RA>:^CP<UYF(5!3_P!G;<?/?\#NHNHX?O59^04445@:A1110`4444`%
M%%%`!1110`DB"5"K#(;@U\^?'_\`X)B_"7]H&2>[NM"_L#6)R6;4-'(MI&8_
MQ.F#&Y]25S[U]"44`?EW\7?^"'OC/PK++/X-\2:3XEM>66"\4V-R!Z9RR,??
M*_05\^^.OV,OBG\*6D_MKP-XA@BC/,\-JUS"?H\>Y?UK]QL9I"H/84`?@%%;
MO;2E)$DCD4X*LI#+]1VK2M^1C@\=J_=3Q)\._#_C)"NKZ'H^JJ1@B[LXY\_]
M]`UQ&L_L7?"C7)-T_P`._".?^F6FQP_^@`4`?#?_``1_?R_VE]2]M`GZ\?\`
M+:"OTN>["XX))K\@?^#C+0T_8A^'?POUGX0W.I_#C5-;U>\L[Z[\/7\]C+=0
MB%&$;%'!*[@#CID"OSA\$?MG_&#7G_TWXK_$RY$@`8/XGO2&^H\VOJ,MX6J8
MS#+$J:2=]->AX]?.(4L0\.XNZ_RN?U-_;5`YX^IJI?\`BJPTNW:6YNK>WC3E
MGEE1%4>N2:_G`\*_%3Q5XDVG4_$_B/4=W!^U:G/-GIUW.?05ZQ\/M%L]4NDD
MN;.VN'SG=+$KM^9%:SX4=/XJGX?\$ZH8Q2U2/VSU_P#:X^&7AF0I>>//"<<H
M./+75(7D_P"^58G/MBLA?VU?!NJ$+HD/B7Q&Y^Z-/T:XV-]))%2/'ONQ7Y^?
M!ZVCM3$L4:1JN``BA0/RKZG^#G+P_2O*Q6`I8?75_,Z8S;5SO/&/[67B6"W9
M])\`M;X!PVNZM%;L#Z[+<3Y^A9<^U>!?%?\`:9^)VOP212^*H-$@;/[K0;%;
M9@/0RRM*YQZH4_"O6_BF!ODX'>OG?XD?ZR7ZFM<OITVU[J^Z_P"9-0^?OB7;
M&]UF?4;N6YO]1G!$EY>7#W-PX]#(Y+$>V<5XEX]E6%9&;(49).*]P^)$@C20
ML54`$DDX`XKWG_@F=_P3Y?XF>)-/^*?C33V30=/F6?P_IURN#J,JD%;R13_R
MR4\QJ?O$;L8"Y^K>,IX6C[6>RV]>QQRIN<M#VO\`X)%?L1R_LR?!>?Q!K]H;
M?QKXU$5S>Q2+\^G6R@F"U]F&YG<?WGQSM!KZ_48`%(D:H3A0/H*=7Y]B<3/$
M576GNST*<%"*B@HHHK%%G)?'7_DC?BW_`+`UU_Z)DK\2O^"$?[`_Q)_:B_9+
MUK7_``A^T=X_^$6G6OB2>S?2-#@\RWGD$$#&<GSD^8A@.G117[=?&6QGU7X5
M^);2VB>>YNM*N(HHT&6D=HG"J/<D@5\.?\&W7[/?CC]FK]B?Q#H7C[PKK7A+
M6+CQ5<7D5GJ=N8)9(6M[=0X![$JPS[5[N6XMT,NK.#7-S1WL^]]&>1B\/[3%
MTFUI:7==NUC/U/\`X-[8OC-JMG)\:/VA_C'\6-/LY1*NG7M]]GMF([8+2%0?
M]D@X)P17WI\&?@]X<^`'POT;P=X2TFTT/P[H$'V:RLK9=L<*9+'W)+$L2<DD
MDDDDUTR\@4M>;B<?B*\5"K*Z6RV2^2T.ZAA*5%MP6KZ]?O"BBC/-<9TVN?D#
M_P`''O@V;XB_MF?L@Z!;ZM?Z#/K>M7EC'J5BVRYL&DN],031'LZ$[@?4"O=T
M_P""'?C!E!_X:_\`VC!_W&#_`/%5S7_!9W]G/Q[\:OVZ_P!DO7/"7A'7?$.C
M^#/$4EWKEY96K2PZ9$;S3G#RL.%&V*0_1#7Z4V[!H5([BOH\1F-2C@L/&A);
M2OHG]I^3MH>)1P,*F)K3JK[2MJU]E=F?FS\8_P#@BMXM\,?"'Q5J<G[6G[0F
MH)IVCW=RUK<:ONBN0D+L8W&[E6Q@CT-)_P`&K9!_X)J:J>@;QOJ''I_HUG7W
M]\>M*N==^!GC2QLX)+F[O-"OH((4&6E=K=U50.Y)('XU\8?\&XOP!\:_LW?L
M":CX>\>^&-9\):X_BZ]O%LM3MS!,T+06JK(%/\)*,`?]DU#Q]2OEU2-:2OS1
MMLN_:P+"PHX^FZ:=N67=]NY]]T445\^>V>=?M3_M'^'_`-E+X!^+/'OB:7R=
M(\+Z?)=R`,`]PX7]W"GJ[N51?=A]:_%K_@D;_P`%!?@KX9_:4^*'[1'Q^\?6
MNG_$[QE?/:Z38-I]U<_V79D`LR-'&R@$".%1G(2$_P!ZOJK_`(+9_!OXQ_M_
M?M(_#;X#^$O"GB:Q^%KZA;ZAXJ\4FV9=.9B2=N_HPAB#,!T:1U'5:^\OA]^Q
MY\,/A]X*TS0K'P#X0%EI%M%9P>;I%O(^R-`B[F*$L<#DDY)YKZ+#U,/A,%:I
M=SJ[V:344]$WKN^G8\6M&M7Q-X62I]T[-OKTV1^8_P#P68_X*%_LG?\`!0?]
MCS4-"T?XFVA\<>&Y?[7\-2G2KU";E1AH-YB`594RO)`#;">E?5O_``0I_P""
M@8_;M_8[T[^V+M9_'?@=$T;7PS?O+DJ,0W1]?-C`)/\`?5Z^HV_9K^'3=?`/
M@K_P1VW_`,17YH^)/V4/B/\`\$W?^"REO\1_A%X&\0>(/@_\5E,?BK3]"LC)
M%I!ED'G-L3A0DNV=,`?*TB#`JJ57"XK"RP<+Q<?>CS-/7K&]EOOZDRA7H8E8
MF;33]V5D_D^NWY'ZR45':OYD"L2<L._6I*^:N>XSR;]NW_DS+XL_]B;JW_I)
M)7Y'_P#!%W_@GY\5/VB_V%;?Q+X-_:9^(GPMTY]7OK>+0M(@+6:2H5S)D3*<
MN2,X7BOU[_;,T"]\6_LI_$K2=+M9[_4]4\+:E:6EK"I:2XEDMG5$4=R20!]:
M^9?^#>[X'>+_`-GO_@GG8^&O'7AG5O"^O1Z]?W+6.I6YAF6-V78^T]C@U]!@
ML7*AEM7D:YN=;V>EGT9Y.)P_M,=#F3MRO9VUT/SP_96_9O?]J/\`;Q\0_`7]
ML?XE_%75/&'AZZ\W0-,N?$#G2?$"J"WREPS`O'^\385+*6&59<']T_A!\+?#
M_P`$_AIH_A3PKI-IH7A[0K<6MC8VR[8X$!/`]22223R223R:^,_^"U7_``3(
MO/VP?AK9?$'X>YTKXS?#@B_T&\M#Y5QJ*1OYGV7>.0X(WQ'L_'`<FO8O^"9W
M[0?Q&^._[.6F2?%GP+XC\"^/]%VV.K0:E9M;1ZBP'RW<.>"KC[RC[K;ATP3>
M:XAXO#PQ-.5DM'#16?=+JG^!.`H_5ZLJ4HW;U4M[KLWW1]'4HZT@H)P*^>/8
M:Z'Y-?\`!QE_R=%^R'_V.3_^E=A71_\`!?;]GS7?A%XD\`_M:_#N`Q^,/A+>
MP)K0C!_TW3B^%9\<E5+M&W_3.9NRUJ?\%UOV;?'_`,>OVB/V8]1\&>$->\36
M/A3Q0UYJ\]A:M*FGPFYLF#R$?=&$<_\``37Z'?$#P+I'Q0^'VK^'=<L8;[1]
M=LI-/O;>505GAE0HZ'V*L17TD<P5"AA*BU24U)>3>J^:/"^J2K5<1%Z7Y;/S
M2T9\1?M\_P#!730?AM_P2ST[XL^"+Q&UWXHZ>+'PK"KAIK>]E0I*Q`YW6V'R
M/[\:CO7%?LM?L&O^P_\`\$1OBG'K<!'CSQQX/U37O$DTHS,DLEG(8[=B>3Y2
M'!S_`!O(>]?._P"PK_P10^(GAO\`X*00>'OB%#K-_P#`OX,:M<:]X7DO07L-
M5EF='@2)3D$[EC>5<8S"0?O5^KO[=/A/4/&?[&GQ1T31;&XU+5=5\*ZE9VEI
M;1EY;B:2VD5$4#J22!5XNIA\(X87"RNI24I/RO[J^2U?F&'C5KJ5>O&S2:2\
M[:OYO;R/E_\`X-H?^44WA;_L,ZI_Z5/7W[7Q/_P0#^"_BW]GW_@G#X>\,>-O
M#NK>%_$%KJNH2RV&H0&&>-'N&9&*GL1R*^V!R*\G.9*6.JRB[KF?YGH9:FL)
M24E9\J_(*\B_;D_:WT/]B#]F;Q3\1]?\N2WT&T+6MLS[6OKI_EA@'N[D#/89
M/:O6KEBENY'4#UK\L/\`@JY\`?BW_P`%,?V\_AO\'X/"?BK1O@;X6NDOO$'B
M*2V>*RU"8C?)L<\,4A'E1G_GI*_;FHRNA3K8A*J[05W+T71>;V*QU6I"B_9*
M\GHO5GSO_P`$5OV^/@1\"?$'Q'^,OQO^)%K'\8OB5J,@FC?3;N8Z?:;][!62
M-E'F28.T$X2*,>HKL/\`@MO^WI^S!^W5^S/:W7@OXFVW_"S_``%?+J_AN1-,
MO(9)VW*);?S&B`7<H5P20-\*=!FOUH\/_LJ_#7P_I5O96_P^\%1VUI$L,*_V
M+;':BC:!RGH!5F[_`&:_AX\)"^`_!BD]"-$M@?\`T"O5><8;ZTL6H2YEM[RM
M9*UK<NUM+'G1RW$>P^KN4;/R=[[WO?>YX7_P1X_;WMO^"@7[&WA[Q)=3Q'Q=
MHB#2/$D(/S+>1*`9<=EE3;(.P+$?PU]6U^3_`,(?V5?B9_P2^_X+'ZS>_#[P
M1XCU_P"`?Q<"-J)TFS::VT"65B07"\*()]Q&!Q!*1VK]7+1B\()).?6O/S;#
MTH5O:8?X))->5]T^UF=^7U*LJ7+67O1T?GY_,DK\N?\`@ZY\%ZIKG[#?@C6;
M2*6XTSP[XRAEU%$!(C62UN(TD;T`?"9]91ZU^HU<;\??@CX>_:0^$VM^!_%F
MG1:KX=\16K6E];2<;D/(93U5U8!E8<@J#6&78Q87%4Z[V3_X?\"L=0]O0E1O
MN9G[)OQ.T3XO?LV>`?$/AR:*XT75_#]E<6CQD;54PJ-F.Q4@J1V*D=J]%!S7
MY.?"_P#9R_:N_P""+FOW^E_##1T_:#^!EQ<R7-MH0NOL^L:+N)9MBD'!SU$8
M=7.6*(2:]6L_^"\>H06?D:A^RO\`M,P:TOR-;0^&?-M]_/'G%E.,XYV5UU\I
MJ3FYX5J<'LTU?YIM-,YZ681C'EQ"<9+R?X-71^AM%?FOX,^*G[:_[>OQZ\,Z
MKI/A]OV:/A7H-V+J[_MG9>:KKB=T>W9<D%3@*5C52=VYB`*_2*SCDC4B1MYP
M!GU]ZX<7A70:C*2;>Z3O;UMI^)V4,0JMVHM+S5K^A-39_P#5&G5'=.(X&8YP
M/2N5&S/P5_X(Y_L(ZW^V/\0/CW<Z3\9?B3\*TT/Q68I8O"U[]G34#)+<$-+R
M,E=I`^IK[H'_``0Y\8?]'@?M&?\`@X/_`,57RA_P37\6_M!?\$U?&_QB1OV6
M_BEXWMO'/B-M0MKBSA-LB1QO,%/*-N#"0$8QTKZO'_!73X^_]&1_&/\`\"!_
M\9K[;-*N.EB92PTH\CM;6'9=]=SY?!0PD:*C74E*[_G[OMH?6/['O[-^H?LL
M?!^'PIJ7CWQ9\1[B&ZFN?[9\13^??.)&R(RV?NKV^M>JC@5\Z_L(_M>^/?VI
MKCQ(OC?X)>,O@_\`V,L!M/[>E\S^T_,,F_R_D7[FQ<_[XKZ*KX_$JHJK]K\7
M6S3_`"T/H\/*G*FG3VZ;_KJ%?E)_P=G1NW[(7PV<(QCC\7'<W9<VDV/Y'\J_
M5NOG7_@J#^P;9?\`!1/]E#6OA_-=0Z;J;.FH:-?R@LEE>Q;MC.!R496=&QSM
M<XR0*Z\HQ$*&,IU:FB3U,,RHRJX6=..[1[YX?U&+5M,BN8'62"X198W!R'5A
MD$>V*J_$&Y2T\$ZK)(P1$M)69CT4!&)-?F%^S/\`\%$/VB?^"?\`X#TWX:_'
M7]GKXE^,X_#,":?8>*/!MM_:OV^WC&V,NH^5F"@#=O4D`;E!R2?M,?\`!1+]
MHG]O_P``:E\-/@7^SS\2_!2>*(WT^_\`%/C2W&E"PMG!678K?(K%21N\QB`3
MM4G!'3_8M95+WCR7^+F5K=_^!N81S*DJ25GS6VL[W'?\&I6X_LK_`!4D"DQ2
M^.I0C_PL19VYX_`C\Z_5.OG'_@ES^P;9?\$[OV3=#\`6]U!J6J>;)J6MZA&I
M5;V]E`WLH/.Q0J(N>2L:DX)Q7T=7/G&*AB,;4K4]F]#?+J$J.&A3GND%%%%>
M:=I^6/\`P=<?\F8_#G_LH%M_Z07M?ISX%_Y$G1_^O*'_`-%K7Y\_\'(_[.WC
MK]I?]EGP)HW@#PGKGB[5+#QK#?7%MIEL9I(8%L[M#(P'10SH,^K5^@_@F-H?
M!VE(Z/&\=I$C*PPRD(`01ZYKU\3*/]G4(WUO/_VT\S#Q?UVK*VEH_J:E%%%>
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M019(3#M\VQF3:V2CC[M>SEU2G4PM3`U)*+DU)-[771]DSR\92J1KPQ,(N2BF
MFEO9_P"1^FE%?G3X?_X+<?$+P'$NG?%+]DSX[Z/KL(VSGPWI8U>UD8=61LQC
M:?JWU-<]\4O^"B/[5/[:^C2^%/@%\`O&GPT&K+Y$_B_QQMTXZ:C<%XHF!PP'
M.X&0CLA.#6<<FQ*?OV2[N2MZ[FKS*CM&[?9)W_(_3>BN`_9@\$>-OAS\$-`T
M;XB>+8O''C&QME34M9BM%M4NY/9%P,`8&[`+8R0"<5W]>9./+)I.YW1;:3:L
M-FD\J(L>U?D;_P`',G[?5OH'ASP_^SUHFM6VE7WC-X;SQ7?L69--T[S,11/L
M!;$CJTC*!G9$."'K]4OBUXOF^'_PSUS6[?2=3UZYTJRDNH=-TZ(RW=^Z*2L,
M2CJ[$`#W-?FC_P`$??V`?&GQ._:)^)_[1'[1O@R6T\8>*]0>RTC0]>L@WV&W
M.TO((I`0%"^7#'W"QOZU[&3>QHREC:^JI[+K*73[M[GF9DZE11PU+1RW?9=?
MOVW.Z_92_P""O_[%_P"R5^SYX7^'GASXG0)I/AFQ2TC<Z-?*]PP&9)G_`'/+
MNY9B?5C7PW>_\%$_A'^R/_P65B^+?PB\6PZ[\+_BJOE>-K&&TGMUL)9I!YLV
MV1%!Q+LN`0#_`,M5XSS^XH_9K^'(''@'P5_X([;_`.(KQ3_@H1_P32\!?M;_
M`+)OBSP5IGA?PQH&NWML;C2-1M-+A@DM;V/YHCN10=I/R,.ZNU=6!S#!1KRY
MXRM4TE>2:UZ_#TW.;%83%NG&SC>%FK)WTZ;]=CZ5T75H-9TJTNK66.XM;J%9
MHIHVW)(C`%6![@@Y!JW7PU_P0B\4_%W1_P!E5?AS\9/!?BGPUKGP\<:?I=]J
MMLR1ZKI_/E!)#PQBP8^/X!'UYK[E%>'BZ'L*\J-[VZK9GKX>M[6FJEK7Z=A)
M/]6WTK\F?^"T/_*9#]C;_L*I_P"G"&OUEEXB;Z&ORN_X+>_!GXIZU^WU^SS\
M2O`'PQ\5_$;3OAVSWVH0Z/;%SN2ZCE$1<`A&8*<$BO2X><5C'S.UXRWTWBUU
M.+.(N6'=NCC_`.E(_5.BOSY'_!77X^`?\F1_&/\`\"!_\9KUO]BW]N_XG?M+
M?%FXT'QC^SK\0/A/ID%D]TNK:U-OMY9%*@0@>6OS$,2.?X37+5RO$4X.<K67
M]Z+_``3-Z>/HU)<L6[^C7YH^JZ**#TKSSL/'/VQOV%?AO^WC\-%\,?$?0(=7
MLX',MG<QL8;S3Y2,&2&5?F0D=1R#W!'%?#TG_!"OXQ?LI64DW[.7[4'C#PU:
MP,7MO#WB",W&GL>H#,A,>,\?\>Y->Z_\%)/B/^UI\$_'/ACQ3\$_#?AOQWX"
MTS+Z[X=48UF]."#AG.#&`05\KYPP&59<BO.(/^"[FO2:*+:?]E']H]?$ZX06
M2>'B]F9?0W!(.,]_*Z5]!@%CH45]7E&47JXMQ=O52V/'Q3PDJC=6+4EL[-7]
M&MSGOV`_^"JWQ=\/_MQK^S/^TMX=TFR\=7*,=)U_2P(X=1(C:10Z+\C+(BL5
MD3;\PVL@.2/TV08S]:_+[]C#]B/XR_M=?\%(K7]JKX\>'+;X=V_AZV%GX6\)
MB82WB*L<B1M,?X0OFR.<X9G;[JJ,']0@,5S9RJ*JQ]DDGRKFY?AYNMOP-\ME
M5<)>TO:^C>[72X4445Y!Z(4444`%%%%`!1110`4444`%%%%`!1110`4444`?
MD5_P=K_\D4^#?_8P7G_I.M?D1\,_]8GX5^N__!VO_P`D4^#?_8P7G_I.M?D1
M\,_];']!7Z[PO_R*J?K+\V?#YA_R,Y?+\CW_`.'_`-U/J*^@/A?UCKY_^'_W
M(_J*]_\`A?UCIXO8]S#_``GTG\)O]9'^%?4GP;^_%]*^6OA-Q(GX5]._##5K
M30M.-[>W-O:6=L@>6::58XXU]2QP`/K7PV;:Z'J4MK'0_%,9DD_&OG#XLZE#
MIBN\K[2[^6B`%GE<G"HJC+,Q/`5023P!7O\`J47B'XX7QA\&Z.]S8R9#:YJ"
MO;:8H_OQ9`DN?;RAL/\`SU%>F?!']CCP[\*]4AUO4))?$OBH*3_:=Y$H%J6Z
MK;1`;(%ZC(RY'#.U<.'Q,*$;SW[=?^`4TWHCYX_94_X)TW'CC6K/Q;\2]-:W
MTJ-Q-8^&YQ\]P0<K+>`'`7H1!G_KIW0?<MK:QV4"QQ($C4851T`]!3HXQ$@4
M9P/6G5P8G%5*\N:;VV78NG34-@HHHKG+"BBB@!KQ*YR1S0D*QDX&,TZBE9`%
M%%%,`HQS110!$;.,L25R3SU-2*H48'`%+12L@$90RD'D&DCA6$848S[TZBF%
M^@4444`,:!&?<1S]:>!@444`%1&SB+9V#-2T4K(!$C$8P!@"EZT44P&/;I(<
MD9/UHCMTB/`Z^]/HH87&O$LB;6&1Z4U+6.,\+C!SU-244N5`%!&X<T44P(S:
M1L02N2.A[TI@4QA,?*!C%/HI60$8M8PP.WD'(.3Q2O`DF=PSGJ*?10DEL`R.
MW2+.T8R,4_I110DEL'F!&1@U&;2,D';TQW]*DHI@`&****5EL`QK9&?<5&0<
MY]Z<B"-<`8%+119`%&***8$9M(R^XKDYSR:!:QA<;1@5)12:0/48MLBG@?J:
M?113L`4DB"1"IY!Z\TM%`$?V6/\`NY_&C[)'_<%244K(!L<*Q?=&*=113`*"
M-P(/0T44`1"SC`X!';@FE^QQD@[>G3FI**5D*RO<14"+@<`4M%%,84444`1M
M:QN22N<^_OFGJH1<#@"EHHL.X4444""F"!!+OQ\WKFGT4K`%%%%,`ILD2RKA
MAD4ZB@35]R,VD9&-O'IDT?94';]34E%*R&&,4444P$=!(I5AD&F+:HA!"X(]
MZDHH`*;)"LJX8<#WQ3J*35]P(X[2.%LJI!^IJ0#`HHI@!&X$'H:8;9&/*YI]
M%*R`C^RQ_P!T4J0)&<@8I]%%EN`4444P&R1+*,,,TW[)'G[N?J:DHH$U?<C%
MM&&#!>0<U)110,****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#\BO
M^#M;_DBOP:_[&"\_])UK\B/AF/WD?X5^NW_!VP<?!3X-^O\`;]Z?_)=:\M_X
M)(?\$&K_`./_`('TOXA_%:ZO=!\*ZBBW.F:';?N[[5(3G;++)_RQB8=`H+L#
MG*\9_4,FS"AA,FA4K.RN_7=GQV*P\ZV9S5-7:M^1\N?#*)]2O;:TMHY+BZG.
M(H(D,DLA]%4`D_@*^RO@/^Q7\7?&D<,EC\//$,$,F")M3B738_KB<J^/HIK]
M8O@;^S!X#_9NTG[!X)\*:)X=MVCV2-:VX$T_3F20_.YXZL37?;!GH.*^<QG%
M,IW5&&GG_P``^CHX-Q7O'PW\'?\`@FUXY8POK_B/1?#D*X#PZ=`^H7!'M+((
MT1O^V<@S7T;X!_8R\%^![FWN[BWN_$NI6I#17FMS?:VB8=&CCXBC.>\:+7JZ
MH%/"J/I2U\[6Q]>K\3MZ:'7&'*,BA$/`Q@#``&,4^BBN0L****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`^'O^"LG[*%M^V5^T?^S'X0U&`7
M.A0>)[_5]7C(^62TMK5971O9V"(?^NE?;=C8Q:=;)#!&L,4:A$11A5`&``/I
M5/4/".G:IXDT_5Y[9)-2TN*6&UG/WH4EV>8!_O>6F?\`=K2'(KIK8F52E3I-
MZ0O^+;,:=",9RJ):O]-`HHHKF-@HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
$B@#_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
